

### **STATEMENT**

We, ACON Laboratories, Inc., having a registered office at 5850 Oberlin Drive #340, San Diego, CA 92121 authorize SRL Sanmedico having a registered office at A. Corobceanu street 7A, apt. 9, Chisinău, MD-2012, Moldova

to register, notify, renew or modify the registration of medical devices on the territory of the Republic of Moldova.

Date: January 3, 2023

Signature:

Qiyi Xie, Md, MPH Sr. Officer, Regulatory & Clinical Affairs ACON Laboratories, Inc. Ph: 858-875-8011 Email: qxie@aconlabs.com









# **EC Certificate**

Full Quality Assurance System Directive 98/79/EC on In Vitro Diagnostic Medical Devices (IVDD), Annex IV excluding (4, 6) (List A and B and devices for self-testing)

## No. V1 104507 0003 Rev. 06

Manufacturer:

### ACON Laboratories, Inc.

5850 Oberlin Drive, #340 San Diego CA 92121 USA

### Product Category(ies): Blood glucose measuring systems for self testing and self-testing devices for clinical chemistry, hematology and pregnancy and ovulation

The Certification Body of TÜV SÜD Product Service GmbH declares that the aforementioned manufacturer has implemented a quality assurance system for design, manufacture and final inspection of the respective devices / device families in accordance with IVDD Annex IV. This quality assurance system conforms to the requirements of this Directive and is subject to periodical surveillance. For marketing of List A devices an additional Annex IV (4) certificate is mandatory. All applicable requirements of the testing and certification regulation of TÜV SÜD Group have to be complied with. For details and certificate validity see: <a href="https://www.tuvsud.com/ps-cert?q=cert:V1104507">www.tuvsud.com/ps-cert?q=cert:V1104507</a>

Report no.:

SH22743EXT01

Valid from: Valid until: 2022-05-04 2025-05-26

Date, 2022-05-04

Christoph Dicks Head of Certification/Notified Body







# **EC Certificate**

Full Quality Assurance System Directive 98/79/EC on In Vitro Diagnostic Medical Devices (IVDD), Annex IV excluding (4, 6) (List A and B and devices for self-testing)

## No. V1 104507 0003 Rev. 06

Model(s):

On Call Plus Blood Glucose Monitoring System, On Call Plus Blood Glucose Test Strips, On Call EZ II Blood Glucose Monitoring System. On Call Advanced Blood Glucose Monitoring System, On Call Advanced Blood Glucose Test Strips, On Call Chosen Blood Glucose Test Strips, On Call Vivid Blood Glucose Monitoring System (OGM-101), On Call Vivid Blood Glucose Test Strips (OGS-101), On Call Sharp Blood Glucose Monitoring System (OGM-121), On Call Sharp Blood Glucose Test Strips (OGS-121) On Call Plus II Blood Glucose Monitoring System (OGM-171), On Call Plus II Blood Glucose Test Strips (OGS-171), On Call Extra Blood Glucose Monitoring System (OGM-191), On Call Extra Blood Glucose Test Strips (OGS-191), On Call GK Dual Blood Glucose & Ketone Monitoring System (OGM-161), On Call Blood Ketone Test Strips (OGS-161), Urinalysis Reagent Strips (Urine), UTI Urinary Tract Infection Test Strips, Cholesterol Monitoring System (CCM-111), CHOL Total Cholesterol Test Devices (CCS-111), TRIG Triglycerides Test Devices (CCS-112), HDL High Density Lipoprotein Test Devices (CCS-113), 3-1 Lipid Panel Test Devices (CCS-114), Cholesterol CTRL Control Devices, Cholesterol Monitoring System (CCM-101), CHOL Total Cholesterol Test Strips (CCS-101), PT/INR Monitoring System (CCM-151), PT/INR Test Strips (CCS-151), Hemoglobin Testing System (CCM-141), Hemoglobin Test Strips (CCS-141), hCG Pregnancy Rapid Test Cassette (Urine), Pregnancy Rapid Test Midstream, On Call Extra Mobile Blood Glucose Monitoring System (OGM-281), On Call Sure Blood Glucose Monitoring System (OGM-211), On Call Sure Sync Blood Glucose Monitoring System (OGM-212), On Call Sure Blood Glucose Test Strips (OGS-211), GIMA Blood Glucose Monitoring System, GIMA Bluetooth Blood Glucose Monitoring System, GIMA Blood Glucose Test Strips, On Call GU Dual Blood Glucose & Uric Acid Monitoring

Page 2 of 3 TÜV SÜD Product Service GmbH is Notified Body with identification no. 0123







# **EC Certificate**

Full Quality Assurance System Directive 98/79/EC on In Vitro Diagnostic Medical Devices (IVDD), Annex IV excluding (4, 6) (List A and B and devices for self-testing)

## No. V1 104507 0003 Rev. 06

System (OGM-201), On Call Blood Uric Acid Test Strips (OGS-201), LH Ovulation Rapid Test Cassette (Urine). **Ovulation Rapid Test Midstream**, **Ovulation & Pregnancy Test Combo Pack**, On Call Extra Voice Blood Glucose Monitoring System (OGM-291), Early Detection Pregnancy Test, Digital Pregnancy Test. Go-Keto Blood Glucose & Ketone Monitoring System (OGM-161). Go-Keto Blood Ketone Test Strips (OGS-161), Go-Keto Blood Glucose Test Strips, On Call Extra GM Blood Glucose Monitoring System(OGM-191). On Call Extra GM Blood Glucose Test Strips (OGS-191), On Call Plus GM Blood Glucose Monitoring System, On Call Plus GM Blood Glucose Test Strips, Go-Keto Urinalysis Reagent Strips

### Facility(ies):

ACON Laboratories, Inc. 5850 Oberlin Drive, #340, San Diego CA 92121, USA

ACON Laboratories, Inc. 10125 Mesa Rim Road, San Diego CA 92121, USA

AZURE Institute, Inc. 10125 Mesa Rim Road, San Diego CA 92121, USA

Acon Laboratories Inc. Guerrero Negro 9942 Parque Industrial Pacifico IV, 22644 Tijuana B.C. CP, MEXICO

## **Declaration of Conformity**

ACON Laboratories, Incorporated 5850 Oberlin Drive #340 San Diego, CA 92121, USA

### We, the manufacturer, declare under our sole responsibility that the in vitro diagnostic device:

*Mission®* Urinalysis Reagent Strips (U031-XX1)

classified as Others in the directive 98/79/EC,

meets all the provisions of the directive 98/79/EC on *in vitro* diagnostic medical devices which apply to it

The self-declaration is according to Annex III (excluding Section 6) of the Directive.

Authorized Representative: Medical Device Safety Service GmbH Schiffgraben 41 30175 Hannover, Germany

Signed this 11 day of February, 2020 in San Diego, CA USA

Qiyi Xie, MD, MPH Senior Staff, Regulatory Affairs & Clinical Affairs Acon Laboratories, Inc.



5850 Oberlin Drive #340-San Diego, CA 92121, USA - Tel: (858) 875-8000 - Fax: (858) 875-8099 E-mail: info@aconlabs.com







# Certificate

No. Q5 104507 0001 Rev. 03

### Holder of Certificate:

### **ACON Laboratories, Inc.**

5850 Oberlin Drive, #340 San Diego CA 92121 USA

**Certification Mark:** 



## Scope of Certificate:

Design and Development, Manufacture and distribution of In Vitro Diagnostic Test Kits and Reagents for the Determination of Infectious Diseases, Clinical Chemistry, Drugs of Abuse, Tumor/Cardiac Marker, Fertility/Pregnancy and Blood Glucose Monitoring System, Lancing Devices and Lancets

The Certification Body of TÜV SÜD Product Service GmbH certifies that the company mentioned above has established and is maintaining a quality management system, which meets the requirements of the listed standard(s). All applicable requirements of the testing and certification regulation of TÜV SÜD Group have to be complied with. For details and certificate validity see: www.tuvsud.com/ps-cert?q=cert:Q5 104507 0001 Rev. 03

Report No.:

SH22743A01

Valid from: Valid until: 2022-09-15 2025-09-06

Date,

2022-09-15

Christoph Dicks Head of Certification/Notified Body





# Certificate

No. Q5 104507 0001 Rev. 03

#### Applied Standard(s): EN ISO 13485:2016 Medical devices - Quality management systems -Requirements for regulatory purposes (ISO 13485:2016) DIN EN ISO 13485:2016

Facility(ies):ACON Laboratories, Inc.<br/>5850 Oberlin Drive, #340, San Diego CA 92121, USA

Address holder for registration only

#### ACON Laboratories, Inc. 10125 Mesa Rim Road, San Diego CA 92121, USA

Manufacture and distribution of In Vitro Diagnostic Test Kits and Reagents for the Determination of Infectious Diseases, Clinical Chemistry, Drugs of Abuse, Tumor/Cardiac Marker, Fertility/Pregnancy and Blood Glucose Monitoring System, Lancing Devices and Lancets

#### ACON Laboratories, Inc. 6865 Flanders Dr., Suite B, San Diego CA 92121, USA

Storage of

In Vitro Diagnostic Test Kits and Reagents for the Determination of Infectious Diseases, Clinical Chemistry, Drugs of Abuse, Tumor/Cardiac Marker, Fertility/Pregnancy and Blood Glucose Monitoring System, Lancing Devices and Lancets

AZURE Institute, Inc. 10125 Mesa Rim Road, San Diego CA 92121, USA

#### Design and Development of

In Vitro Diagnostic Test Kits and Reagents for the Determination of Infectious Diseases, Clinical Chemistry, Drugs of Abuse, Tumor/Cardiac Marker, Fertility/Pregnancy and Blood Glucose Monitoring System, Lancing Devices and Lancets

Acon Laboratories Inc. Guerrero Negro 9942 Parque Industrial Pacifico IV, 22644 Tijuana B.C. CP, MEXICO

Manufacture of blood glucose test strips, antigen rapid test and IgG/IgM antibody rapid test for infectious disease.

# **Mission® Urinalysis Reagent Strips** and Urine Analyzers



Obtain reliable and cost-effective results with Mission<sup>®</sup> Urinalysis Reagent Strips and Urine Analyzers!

- Accurate
- Reliable
- Convenient



# **Urinalysis Reagent Strips**



#### Simple and Accurate

- Analytical sensitivity better than or comparable to market leaders
- · High quality color chart ensures accurate visual reading

#### Flexible

- Compatible for visual and analyzer reading
- · More than 30 different combinations available

#### Multiple Packaging Options and Long Shelf Life

- Canister Packaging
   Available in 25, 50, 100 and 150 strips per kit
- · 2 year shelf life for unopened canisters which offers cost savings and convenience for high volume testing
- · 3 month shelf life for strips in opened canisters
- Pouch Packaging New! Single-strip Pouch
  - . Individually packaged strips with 1, 3, 6 and 20 strips and 1 color chart per kit for OTC or low volume testing
  - . Unique packaging maintains 2 year shelf life for all strips in the kit compared to 3 months for remaining strips in an opened canister
- Multi-strip Pouch
  - Canister Refill Kits with 25 strips/pouch uniquely packaged to save cost for low volume testing and extended shelf life by using the canister for refills







Step 3: Obtain results by analyzer or visual reading

Ste	ep 1: Immers	e strip into	o urine		Step 2: Remove excess urine			ne S	Step 3: Obtain results by analyzer or visual reading													
Catalog	No. of	Type of Strip*		String por	Douch	Read	ing Me	thod	Analyzer-Read					Ê	aran	nete	rs					
No.	Parameters	For Visual Reading	For Analyzer Reading	Canister*	Packaging <sup>*</sup>	Visual	U120	U500	Strips: Standard (S) or Additional (A)	ASC	GLU	BIL	KET	SG	BLO	pН	PRO	URO	NIT	LEU	ALB	CRE
U031-131	13	130	NA	100*	×	1	NA	NA	A	*	*	*	*	*	*	*	*	*	*	*	*	*
U031-111	11		11A	100		1	1	1	S	*	*	*	*	*	*	*	*	*	*	*	_	
0001111	1.0	12	10U	1 100		1	1	1	S		*	*	*	*	*	*	*	*	*	*		1
1031-101	10		104	100	~	1		-	A	*	*	*	*	*	*	*	*	*	*			
	10		10C	100*		1	~	1	S		*		*	*	*	*	*		*	*	*	*
U031-091	9		90	100	~	~	~	1	S		*	*	*	*	*	*	*	*	*	_		
			8U			1	~	1	A		*	*	*		*	*	*	*	*			1
U031-081	8		8N	100	~	~	~	1	S		*		*	*	*	*	*		*	*		
			8S			1	~	~	A		*		1	*	*	*	*	*	*	*		
U031-071	7		7N	100	~	~	~	1	А		*		*		*	*	*		*	*		
U031-061	6	6N	6NE	100	1	~	~	~	А		*				*	*	*		*	*		
0001-001	0	6U	6UE	100		$\checkmark$	~	4				*	1	*	*		*	*	*			
		5B	5BE			1	1				*		*		*	*	*					
U031-051	5	5N	5NE	100		1	~	~			*				*		*		*	*		
0001-001	5S	5SE	,		1	~				*			*	*	*	*						
		50	5UE			1	~					*	_		*			*	*	*		
		4S	4SE			~	~	~			*		0	*		*	*	_				
		4B	4BE			1	~		A		*				*	*	*					
U031-041	4	4K	4KE	100	~	~	1	1			*		*			*	*					
		4G	4GE			~	~				*				*		*			*		
		4N	4NE			~	1	1							*		*		*	*		
		4P	4PE			4	~	~			*		ų.				*		*	*		
		3P	3PE			×	~	~	5 S		*	_		_		*	*				$\vdash$	
U031-031	3	3K	3KE	100	~	~	×	×	А		*		*				*				$\vdash$	
		3G	3GE			~	~	~			*		*	_		*						
		30	3NE			*	~	V (				-		-	*		121		*	*		
		20	2GE		4	*	*	*		-	-			_			•					
		21	ONE		6	•	*	*	5		~	-	~	_		-		-	-	-		
U031-021	2	211	2NE 2RE	100	~	V	*	*	А		-		-	-	*	-	_			*		
		20	200			· ·	-	×			^	1 1	~	-			-		*	*	<u> </u>	
		28	20L			~	1	1				-		*	-	*			~	~		
		2C	2CE	100*		~	~	1			1										*	*
		1B	1BE			1	~		-				1		*		1	1				
		1P	1PE	1		1	1	1								*						
U031-011	1	1G	1GE	100	~	1	~	1	А		*											
		1K	1KE	1		1	1	1					*									
		18	185			1	1	1			-	<u> </u>					*	_				

♦Type of Strip:

Visual Strip Size

1-6 Parameters: 5 mm x 80 mm; 7-11 Parameters: 5 mm x 108 mm; 12-13 Parameters: 5 mm x 121 mm U120/U500 Strip Size

Also available in canisters of 25, 50 and 150 strips Not available in canisters of 150 strips

▲ Single-strip Pouch available in 1,3, 6 and 20 strip kit Canister Refill Kit, with 25 strips per pouch or canister, available in 3-pouch and 1- canister kit, or 4-pouch kit

1-11 Parameters: 5 mm x 108 mm:

"E" means extended strip length for 1-6 Parameters

CE Marked for sale in the European Community Cleared for US 510(k)

F

# U120 Urine Analyzer





- Up to 120 tests/hour in Continuous Test Option
- · Capable of reading 1 strip at a time in Single Test Option
- · Test modes include Routine, STAT and QC
- · Automatic calibration for accurate results and easy operation

### Reliable

 Can read up to 4 Strip combinations with 8, 9, 10, 11 parameters, additional strips with 1-11 parameters available upon request · Minimal training required

- Convenient Operation Saves and recalls the last 2,000 results automatically
- · Audible beep signals operator to dip strips in urine
- · Can print up to 3 copies per test for convenient reviewing and easy record keeping · Option to print results on sticker paper for quick and simple record management

#### Easy Data Management

Includes RS232C port for easy data transfer to an external computer or LIS
 Optional Barcode Reader to record patient ID

#### Unique Lockout Functions new!

- · Strip Lockout Prevents using strips of another brand on the U120 Urine Analyzer
  - · Requires barcode reader scan or manual entry of the canister code
- User Lockout
- Eliminates unapproved users from testing
   Up to 10 lab operators can perform testing, but only the lab administrator can change analyzer settings • QC Lockout
- · Prevents testing without passing QC QC tests can be performed once every 8 hours, day, week or month • Analyzer will alert when to run QC test
- . If QC tests fail, analyzer will switch to STAT mode and list "E" at the end of each test number

#### Specifications

Feature	Specifi	cations		
Analyzer Type	Manual			
Methodology	Reflectance Photometry			
Detection	Photosensitive Diode			
Throughput	Single Test Option: 60 tests/hour Continuous Test Option: 120 tests/hour			
Test Modes	Routine, STAT and QC			
Lockout Functions	Strip Lockout: Available Upon Request: Use	er/QC Lockout: Included with option to turn ON/OFF		
Memory	Last 2,000 results			
Strip Incubation Time	1 Minute			
Wavelength of Monochromatic LED	525 nm and 635 nm			
Standard Strips	8, 9, 10, 11 Parameters (5 mm x 108 mm	)		
Additional Strips Available	1-11 Parameters (5 mm x 108 mm); see UF	RS Parameters		
Total Combinations Per Analyzer	4 Combinations			
Analyzer Ports	Standard RS232C Port for Barcode Rea USB Port for Data Transfer 25 Pin Parallel Port for External Printer	ider or Data Transfer		
Capabilities	Internal Thermal Printer (included) Optional External Printer (not included)	RS232C Barcode Reader (optional) USB or RS232C Data Transfer Cable (optional)		
Major Readable Barcodes	Code 128, Code 39, Codabar (NW-7), Inter EAN 8, EAN 13	leaved 25, UPC-A, UPC-E,		
Calibration	Automatic			
Available Languages on the Screen	English and additional language(s)			
Operating Conditions	0-40°C (32-104°F); ≤85% RH			
Storage Conditions	-5-50°C (23-122°F); ≤90% RH			
Power Source	100-240 VAC, 50-60 Hz			
Dimensions (L x W x H)	27.2 cm x 26.9 cm x 14.6 cm (10.7" x 10.	6" x 5.7" )		
Display Dimensions (L x W)	10.8 cm x 5.7 cm (4.2" x 2.2")			
Weight	2.6 kg (5.7 lbs)			

#### **Ordering Information**

Product Name	Catalog No.	Col	mponents		Kit Box Dimensions (L x W x H) & Weight	Carton Dimensions (L x W x H) & Weight	Number of Kits/Carton	
11120 Urine Analyzer	1 Urine Analyzer			2 Fuses (2.0A) 1 Power Cord	42.0 cm x 41.5 cm x 3	1		
o izo ofine Analyzer	0111-101	2 Printer Paper Roll	Paper Rolls 1 Quick Start Guide 16.4" x 16.2" x 12.1"; 176.4 oz		<u> </u>			
U120 Urine Analyzer		1 Urine Analyzer 1 Strip holder		2 Fuses (2.0A) 1 Power Cord	44.5cm x 44.5cm x 4	0.0cm; 5.5 kg		
with Barcode Reader	omin	2 Printer Paper Rolls 1 Barcode Reader (RS232C)		1 Serial Splitter Cable (RS232C) 1 Quick Start Guide 1 Instruction Manual	17.5" x 17.5" x 15.			
Barcode Reader	U221-111 <sup>à</sup>	1 Barcode Reader (F	RS232C)	1 Serial Splitter Cable (RS232C)	23.6 cm x 10.8 cm x 7.8 cm; 0.482 kg 9.3" x 4.3" x 3.1"; 17.0 oz	63.0 cm x 37.0 cm x 30.0 cm; 12.0 kg 24.8" x 14.6" x 11.8"; 423.3 oz	22	
Printer Paper Rolls	1404 404	4 Printer Paper Polls	Thermal Paper (0.06 m x 20 m): 200 results/roll		12.0 cm x 12.0 cm x 6.5 cm; 0.36kg 4.7" x 4.7" x 2.6"; 12.7oz	63.0 cm x 37.0 cm x 30.0 cm; 19.4 kg 24.8" x 14.6" x 11.8"; 684.3 oz	- 50	
T miler r aper reals	0121-101	Sticker P		per (0.06 m x 9 m): 100 results/roll	12.0 cm x 12.0 cm x 6.5 cm; 0.4 kg 4.7" x 4.7" x 2.6"; 14.1 oz	5 cm; 0.4 kg 63.0 cm x 37.0 cm x 30.0 cm; 21.4 kg 14.1 oz 24.8" x 14.6" x 11.8"; 684.3 oz; 754.9		
U120 Data Transfer Kit	U221-131√ <sup>†</sup>	1 Data Transfer Cable	(RS232C)	1 Package Insert	16.0 cm x 13.0 cm x 3.5 cm; 0.147 kg 6.3" x 5.1" x 1.4"; 5.2 oz	25.0 cm x 21.0 cm x 15.0 cm; 1.36 kg 9.8" x 8.3" x 5.9"; 48.0 oz	8	



# **U500 Urine Analyzer**



- Accurate and Efficient Up to 500 tests/hour for medium/large volume sample testing Professional accuracy equivalent to market leader Automatic strip detection and alignment for better efficiency Test modes include Routine, STAT and QC

Easy to Operate
 Large buch screen LCD offers simple menu navigation
 Uniquely designed strip platform/waste tray unit for easy one-step cleaning

#### Convenient

- Convenient Automatic calibration and waste disposal reduce hands-on time Can read strips with 8, 9, 10, 11 parameters, additional strips with 1-11 parameters available upon request Strip selection of up to 4 combinations for analyzer reading Stores up to 2,000 records and automatically flags abnormal results Capable of printing results on sticker paper for quick and easy record management

Data Management Capability • Includes RS232C port for easy data transfer to an external computer or LIS • Optional Barcode Reader to record patient ID Unique Lockout Functions <sup>Coming Scont</sup>

- Strip Lockout
   Prevents using strips of another brand on the U500 Urine Analyzer
   Requires barcode reader scan or manual entry of the canister code
- User Lockout
- Eliminates unapproved users from testing
   Up to 10 lab operators can perform testing, but only the lab administrator can change analyzer settings QC Lockout
   Prevents testing without passing QC
- - QC tests can be performed once every 8 hours, day, week or month
     Analyzer will alert when to run QC test

  - . If QC tests fail, analyzer will switch to STAT mode and list "E" at the end of each test number

#### Specifications

Feature	Specifications				
Analyzer Type	Semi-Automatic				
Methodology	Reflectance Photometry				
Detection	Photosensitive Diode				
Throughput	500 tests/hour (Measuring cycle: 7 seconds/test)				
Test Modes	Routine, STAT and QC				
Lockout Functions	Strip Lockout: Available Upon Request; User/QC Lockout: Included with option to turn ON/OFF				
Memory	Last 2,000 Records				
Strip Incubation Time	1 Minute				
Wavelength	525 and 635 nm				
Standard Strips	8, 9, 10, 11 Parameters (5 mm x 108 mm)				
Additional Strips Available	1-11 Parameters (5 mm x 108 mm); see URS Parameters				
Total Combinations Per Analyzer	4 Combinations				
Waste Disposal Capacity	Up to 150 Strips				
Analyzer Ports	Standard RS232C Port for Barcode Reader or Data Transfer 25 Pin Parallel Port for External Printer				
Capabilities	Internal Thermal Printer (included) RS232C Barcode Reader (optional) Optional External Printer (not included) RS232C Data Transfer Cable (optional)				
Major Readable Barcodes	Code 128, Code 39, Codabar (NW-7), Interleaved 25, UPC-A, UPC-E, EAN 8, EAN 13				
Calibration	Automatic				
Available Languages on the Screen	English and additional language(s)				
Operating Conditions	0-40°C (32-104°F); ≤85% RH				
Storage Conditions	-5-50°C (23-122°F); ≤90% RH				
Power Source	100-240 VAC, 50-60 Hz				
Dimensions (L x W x H)	36.6 cm x 28.3 cm x 19.5cm (14.4" x 11.1" x 7.7")				
Display Dimensions (L x W)	11.5 cm x 9.0 cm (4.5" x 3.5")				
Weight	4.0 kg (8.8 lbs)				

#### **Ordering Information**

Product Name	Catalog No.	Co	mponents		Kit Box Dimensions (L x W x H) & Weight	Carton Dimensions (L x W x H) & Weight	Number of Kits/Carton		
	1 Urine Analyzer 2 Fuses (2.0A) 1 Strip Platform/Waste Tray 1 Power Cord		51.0 cm x 42.0 cm x 3						
0500 Urine Analyzer	U211-101	2 Printer Paper Roll	s	1 Instruction Manual	20.1" X 16.5" x 15.	1			
U500 Urine Analyzer	ne Analyzer 2 Fuses (2.0A) I Strip Platform/Waste Tray 1 Power Cord		55.0 cm x 55.0 cm x	55.0cm; 9.2 kg	1				
with Barcode Reader	0211-111	2 Printer Paper Rolls 1 Barcode Reader (RS232C)		1 Serial Splitter Cable (RS232C) 1 Instruction Manual	21.7" x 21.7" x 21.	7"; 324.5 oz			
Barcode Reader	U221-111à	1 Barcode Reader (I	RS232C)	1 Serial Splitter Cable (RS232C)	23.6 cm x10.8 cm x 7.8 cm; 0. 482 kg 9.3" x 4.3" x 3.1"; 17.0 oz	63.0 cm x 37.0 cm x 30.0 cm; 12 kg 24.8" x 14.6" x 11.8"; 423.3 oz	22		
Printer Paper Rolls	1000 101	aner Rolls Licos dos A Printer Paner Pr		per Rolls Thermal Paper (0.06 m x 20 m): 200 results/roll Sticker Paper (0.06 m x 9 m): 100 results/roll		12.0 cm x 12.0 cm x 6.5 cm; 0.360 kg 4.7" x 4.7" x 2.6"; 12.7 oz	63.0 cm x 37.0 cm x 30.0 cm; 19.4 kg 24.8" x 14.6" x 11.8"; 684.3 oz	50	
	0121-101	41 miler r uper rons	12.0 cm x 12.0 cm x 6.5 cm; 0.40 kg 4.7" x 4.7" x 2.6"; 14.1oz			63.0 cm x 37.0 cm x 30.0 cm; 21.4 kg 24.8" x 14.6" x 11.8"; 684.3 oz; 754.9 oz			
U500 Data Transfer Kit	U221-131√	1 Data Transfer Cable	e (RS232C)	1 Package Insert	16.0 cm x 13.0 cm x 3.5 cm; 0.147kg 6.3" x 5.1" x 1.4"; 5.2 oz	25.0 cm x 21.0 cm x 15.0 cm; 1.36 kg 9.8" x 8.3" x 5.9"; 48.0 oz	8		

### We also offer other rapid diagnostic and medical products:

Blood Glucose Monitoring Systems, Immunoassay EIA/ELISA and more.

✓ CE Marked for sale in the European Community



ACON Laboratories, Inc., 10125 Mesa Rim Road, San Diego, CA 92121, U.S.A. • Tel: 1-858-875-8000 • Fax: 1-858-200-0729 • E-mail: info@aconlabs.com Please visit our website for details: www.aconlabs.com



Date: 05/Jan/2023

### STATEMENT

We, Atlas Medical having a registered office at Ludwig-Erhard-Ring 3, 15827 Blankenfelde-Mahlow, Berlin, Germany assign SRL Sammedico having a registered office at A. Corobceanu Street 7A, apt.9, Chisinau MD-2012, Moldova, as authorized representative in correspondence with the conditions of directive 98/79/EEC.

We declare that the company mentioned above is authorized to register, notify, renew or modify the registration of medical devices on the territory of the Republic of Moldova.

On Behalf of Manufacturer: General Manager Haya Amawi Signature: Date: <u>S. 61.202</u>L0dwig - Erhard Ring 3 15827 Blankenfelde - Mahlow 15827 Blankenfelde - Mahlow Tel. (0049) 33708 - 355030

> Atlas Medical: Ludwig-Erhard-Ring 3, 15827 Blankenfelde-Mahlow, Berlin, Germany, <u>Tel:+4933708355030</u>

Regulatory Office: William James House, Cowley Rd, Cambridge, CB4 0WX, United Kingdom Tel: +44 (0) 1223 858 910

Middle East Site: P.O Box 204, King Abdullah II Industrial Estate, Amman, 11512, Jordan Tel: +962 6 4026468



Declaration Ref No: DC22-0015

Date : 13.05.2022

### **CE Declaration of Conformity**

We, Atlas Medical GmbH Head office: Ludwig-Erhard-Ring 3 15827 Blankenefelde-Mahlow Germany Tel: +49(0)33708355030 Email: info@atlas-site.com

Middle East Site: : Sahab Industrial Zone Area, King Abdullah II Industrial City Amman 11512, Jordan Tel.: +962 6 4026468 Fax: +962 6 4022588 Email: info@atlas-medical.com

Declare our responsibility that the following product: **Blood Grouping Reagents:** (Anti-A Monoclonal Reagent, Anti-B Monoclonal Reagent, Anti-AB Monoclonal Reagent and Anti-D IgG/IgG blend Reagent) see the attached list of variants That are classified as Annex II, list A Is produced under Atlas quality system (ISO13485: 2016) supported by GMED certificate and complies with the essential requirements of In Vitro Diagnostic Medical Devices Directive 98/79/EC And EN ISO 18113-1, -2 :2011, EN ISO 15223:2016 EN ISO 14971:2019, EN ISO 23640 :2015 , ISO 2859 :2017, EN 13612:2002, EN 13641:2002, EN 13975:2003, EN ISO 13485:2016, EN 62366-1:2020 And Intended for In-Vitro Professional use only. **Conformity Assessment Route:** Annex IV.3 – Approval full Quality Assurance System. Annex IV.4-EC Design Examination (of the product) Notified Body: G-MED CE 0459

GMED, Laboratoire national de métrologie et d'essais 1 rue Gaston Boissier 75015 Paris Tél. : 01 40 43 37 00 , TVA:FR 28 839 022 522

**EC Certificates No.:** 

- CE Certificate of Approval full Quality Assurance System: 33540 rev4.
- CE Certificate Of EC Design Examination: 33544 rev3.

Atlas Modical	Start of CE Marking	Date of expiry	Name & Position	Signature	
GmbH	09 <sup>th</sup> october 2017	26 <sup>th</sup> May 2025	Amani Al-habahbeh	Signature	MRXDO10F.11
CINDIT			(RA Manager)	Amar	21.10.2013

Atlas Medical







Product Code	Product Name	GMDN Code
8.02.00.0.0010	Anti-A Monoclonal Reagent (Titer: 1/512), 10ml/vial, 1 vial/Carton Box	52532
8.02.00.1.0100	Anti-A Monoclonal Reagent (Titer: 1/512), 10ml/vial. 10 vials / Plastic Pack	52532
8.02.00.1.0180	Anti-A Monoclonal Reagent (Titer: 1/512), 10ml/vial, 18 vials / Carton Box	52532
8.02.01.0.0010	Anti-B Monoclonal Reagent (Titer: 1/512), 10ml/vial, / Carton Box	52538
8.02.01.1.0100	Anti-B Monoclonal Reagent (Titer: 1/512), 10ml/vial, 10 vials / Plastic Pack	52538
8.02.01.1.0180	Anti-B Monoclonal Reagent (Titer: 1/512), 10ml/vial, 18 vials / Carton Box	52538
8.02.02.0.0010	Anti-AB Monoclonal Reagent (Titer: 1/512), 10ml/vial, 1 vial/ Carton Box	46442
8.02.02.1.0100	Anti-AB Monoclonal Reagent (Titer: 1/512), 10ml/vial, 10 vials/Plastic Pack	46442
8.02.02.1.0180	Anti-AB Monoclonal Reagent (Titer: 1/512), 10ml/vial, 18 vials/Carton Box	46442
8.02.03.0.0010	Anti-D IgG/IgM Blend Reagent (Titer: 1/128), 10ml/vial, 1 vial/ Carton Box	52647
8.02.03.1.0100	Anti-D IgG/IgM Blend Reagent (Titer: 1/128), 10ml/vial, 10 vials / Plastic Pack	52647
8.02.03.1.0180	Anti-D IgG/IgM Blend Reagent (Titer: 1/128), 10ml/vial, 18 vials / Carton Box	52647
8.02.04.0.0010	Anti-A Monoclonal Reagent (Titer: 1/256), 10ml/vial, 1 Vial/Carton Box	52532
8.02.04.0.0100	Anti-A Monoclonal Reagent (Titer: 1/256), 10ml/vial, 10 vials / Plastic Pack	52532
8.02.05.0.0010	Anti-B Monoclonal Reagent (Titer: 1/256), 10ml/vial, 1vial/Carton Box	52538
8.02.05.0.0100	Anti-B Monoclonal Reagent (Titer: 1/256), 10ml/vial, 10 vials /Plastic Pa	ck 52538
8.02.05.6.0030	ABO Set (Anti-A (1/256), Anti-B (1/256), Anti-D (1/64)),3x10ml / plastic Pack	45308
8.02.05.7.0020	ABO Set: Anti-A (1/256), Anti-B (1/256), 2x10ml /Plastic Pack	52695
8.02.06.0.0010	Anti-AB Monoclonal Reagent (Titer: 1/256), 10ml/vial, 1vial/Carton Bo	x 46442
8.02.06.1.0100	Anti-AB Monoclonal Reagent (Titer: 1/256), 10ml/vial,10 vials /Plastic Pack	46442
8.02.06.1.0180	Anti-AB Monoclonal Reagent (Titer: 1/256), 10ml/vial,18 vials / Cartor Box	n 45308
8.02.07.0.0010	Anti-D IgG/IgM Blend Reagent (Titer: 1/64), 10ml/vial, 1Vial/ Carton B	Box 52647
8.02.07.1.0100	Anti-D lgG/lgM Blend Reagent (Titer: 1/64), 10ml/vial, 10 vials / Plast Pack	ic 5264

Atlas Medical

Atlas	Start of CE Marking	Date of expiry	Name & Position	Signature,	MRXDO10F.11
Medical GmbH	09 <sup>th</sup> october 2017	26 <sup>th</sup> May 2025	Amani Al-habahbeh- (RA Manager)	Anou	21.10.2013

**Atlas** Medical Quality Diagnostic Products





#### Declaration Ref No: DC22-0015

#### Date : 13.05.2022

8.02.47.0.0030	ABO Set (Anti-A (1/512), Anti-B (1/512), Anti-D (1/128)),3x10ml/Plastic Pack	45308
8.02.47.1.0030	ABO Set (Anti-A (1/256), Anti-B (1/256), Anti-D (1/64)), 3x10ml /Carton Box.	45308
8.02.47.3.0030	ABO Set (Anti-A (1/256), Anti-B (1/256), Anti-D (1/64)), 3x10ml /Plastic Pack	45308
8.02.47.5.0030	ABO Set (Anti-A (1/256), Anti-B (1/256), Anti-D (1/128)), 3x10ml/Plastic Pack	45308
8.02.49.0.0040	ABO Set (Anti-A (1/256), Anti-B (1/256), Anti-AB (1/256), Anti-D (1/64)), 4x10ml/Carton Box	45308
8.02.49.2.0040	ABO Set (Anti-A (1/256), Anti-B (1/256), Anti-AB (1/256), Anti-D (1/128)), 4 x 10ml, 4 vials/Plastic Pack	45308
8.02.53.0.0040	ABO Set (Anti-A (1/512), Anti-B (1/512), Anti-AB (1/512) Anti-D (1/128)), 4x10ml/Plastic Pack	45308
8.02.53.1.0040	ABO Set (Anti-A (1/512), Anti-B (1/512), Anti-AB (1/512) Anti-D (1/128)), 4x10ml, 4vials/Plastic Pack	45308
8.02.70.0.0010	Anti-A monoclonal reagent , Titer (1/1024), 10 ml/vial, 1Vial/ Carton Box	52532
8.02.71.0.0010	Anti-B Monoclonal reagent (Titer: 1/1024), 10 ml/vial .1Vial/ Carton Box	52538
3.02.72.0.0010	Anti-AB Monoclonal reagent (Titer: 1/1024) , 10 ml/vial , 1Vial/ Carton Box	45308
3.02.85.0.0010	Anti-D IgG/IgM Blend Reagent , Titer 1/256, 10ml/vial, 1Vial/ Carton Box	52647

_	29991
6	Atlas Medical
	Quality Diagnostic Products

Atlas	Start of CE Marking	Date of expiry	Name & Position	Signature	MRXDO10F.11
Medical GmbH	09 <sup>th</sup> october 2017	26 <sup>th</sup> May 2025	Amani Al-habahbeh (RA Manager)	Anon	21.10.2013





Declaration Ref No: DC21-0035

## **CE** Declaration of Conformity

According to Annex III of the IVD Directive 98/79/EC

We,

**Atlas Medical** 

Head office: Ludwig-Erhard-Ring 3 Blankenfelde-Mahlow, Germany. Tel: +49 - 33708 – 3550 30 Email: <u>info@atlas-medical.com</u>

Middle East Site: Sahab Free Zone Area, P. O. Box 212555, Amman, Jordan. Tel.: +962 6 4026468 Fax: +962 6 4022588 Email: <u>info@atlas-medical.com</u>

Declare our responsibility that the following product:

### See Attached list

- Comply with all essential requirements (AnnexI) of the IVD Directive 98/79/EC. This compliance has been properly documented and covers the items listed in Annex I of the IVD Directive.
- This product is produced under Atlas quality system (ISO13485:2016) issued by GMED: Certificate N<sup>0</sup>.: 36655 rev 1 Expiry Date: October 8 <sup>th</sup>.2023
- Comply with the essential requirements of following standards (EN 18113-1, -2,-4:2011, EN ISO 15223:2016, EN ISO 23640:2015, EN ISO 14971:2019, ISO 2859/1:1999, EN ISO 13612:2002, EN ISO 13641:2002.

And Intended for In-Vitro Professional use only.

Manufacturer Atlas Medical Ludwig-Erhard-Ring 3 Blankenfelde-Mahlow, Germany.

Blankenf	elde-Mahlow , G	Germany.	Atlas Medical	
Atlas	Issue date	Date of review	Quality Diagnor Management approval	MRXDO10F.10
Medical	March.2021	09.03.2021		08.02.2011



## **CE Declaration of Conformity**

### According to Annex III of the IVD Directive 98/79/EC

Product Description8.00.02.0.0100 : ASO Latex Kit, 100 Tests (4ml Latex, 2x1.0ml controls).8.00.00.0.0100: CRP Latex Kit, 100 Tests (4ml Latex, 2x1.0 ml Controls)8.00.04.0.0100: RF Latex Kit, 100 Tests (4ml Latex, 2x1.0ml controls)8.00.17.0.0100: D-Dimer Latex Kit, 100 Tests8.00.13.0.0300 : Streptococcus Latex Kit, 6 Groups, 6x50 Tests (5x1.5ml Latex(A,B,C,G,F), 1x3ml Latex(D), 1x1.0ml Positive Control, 1x2ml Extraction Reagent E, 1x1.5ml Extraction Reagent 1, 1x1.5ml Extraction Reagent 2, 2x2.5ml Extraction Reagent 3, Stirring Sticks, Glass Slide).8.00.18.3.0500 : RPR Syphilis (Coarse Grain) Kit, 500 Tests (10 ml latex, 2x1ml control)Without card, stirring sticks.

8.00.18.3.1000 RPR Carbon Antigen (Coarse Grain) Kit, 1000 Tests (Reagent only).

Atlas Medical Quality Diagnostic Products



Date: 15.10.2021

# **CE Declaration of Conformity**

Name and address of Manufacturer	Atlas Medical GmbH
	Ludwig-Erhard-Ring 3, 15827 Blankenefelde-Mahlow Germany.
	Tel: +49(0)33708355030
	Email: info@atlas-medical.com

Atlas Medical GmbH declared our his own responsibility that the following IVD medical devices:

Product Code	Product Name	GMDN code
8.17.003.0300	Atlas Periodic Acid Schiff (PAS) Stain Kit, 3x100ml	12597
8.17.004.0300	Atlas Iron Stain Kit, 3x100ml	43307
8.17.009.1000	Atlas Gram Stain Kit	43307
8.17.010.0750	Atlas ZN (Kinyoun) stain pack , 3x250ml	43735
8.15.144.0250	Atlas ZN Decolouriser, 250 ml /Bottle	43307
8.17.015.0500	Atlas Diff-3 Stain.	43307
8.17.016.1000	Atlas Papanicolau Stain Pack.	43587
8.17.110.0250	Atlas Papanicolau Stain EA35, 250 ml /Bottle	43367
8.17.111.0250	Atlas Papanicolau Stain EA36, 250 ml /Bottle	43367
8.17.112.0250	Atlas Papanicolau Stain EA65, 250 ml /Bottle	43387
8.17.114.0250	Atlas Papanicolau Stain EA50, 250 ml /Bottle	43587
8.17.115.0250	Atlas Papanicolau Stain OG6, 250 ml /Bottle	43587
8 17 014 1000	Atlas Reticulocytes stain (Methylene Blue) 1000 ml	43587
0.17.014.1000	/Bottle	43387
8.15.037.0250	Atlas Eosin Y (1%) Stain, 250 ml/Bottle	42507
8.15.038.0250	Atlas Eosin Y (5%) Stain, 250 ml/Bottle	43587
8.15.041.0250	Atlas Field Stain (Solution A), 250ml/Bottle	43587
8.15.042.0250	Atlas Field Stain (Solution B), 250ml/Bottle	43587
8.15.043.0750	Atlas Field Stain Kit 3x250ml (250ml Eiving Reagant	43587
	250ml Eosin Reagent, 250ml Methylene Blue Roagent)	43587
8.15.047.0250	Atlas Giemsa Stain, 250 ml/Bottle	42507
8.15.059.0250	Atlas Haematoxylin Harris Stain 250 ml/Bottle	43587
8.15.069.0250	Atlas Leishman Stain , 250 ml/Bottle	43587
8.15.069.1000	Atlas Leishman Stain 1000 ml/Bottlo	4358/
8.15.074.0250	Atlas Lugol's Iodine 250 ml/Bottle	43587
8.15.078.0250	Atlas May Grunwald Stain 250 ml/Bettle	43587
0.15.105.0050	Atlas New Methylene Blue for Betievlander 250	43587
8.15.105.0250	ml/Bottle	43587
8.15.143.0250	Atlas Wright's Stain, 250 ml/Pottlo	
8.15.146.0100	Atlas Immersion oil 100 Rottle/David	43587
	BOULLE/BOX	43587



### Declaration Ref No: DC21-0249

Date: 15.10.2021

Meets the essential requirments of In Vitro Diagnostic Medical Devices Directive 98/79/EC Annex I And

EN ISO 13485 :2016, EN 18113-1, -2,:2011, EN ISO 15223:2016 EN ISO 14971:2019, EN ISO 23640:2015, ISO 2859/1:1999, EN ISO 13612:2002, EN ISO 13641:2002, EN ISO 62366-1+A1:2020.

IVD Categorization	Directive 98/79, Other IVDs (Non-annex II, non-self-test).
Conformity Assesment Route	Directive 98/79/EC , Annex III.
Name , Address and Identification number of notified body	N/A

Date of issuance:	15. October.2021
Place	Atlas Medical GmbH
Signed by:	Amani AL-Habahbeh
Position :	Ame
	Regulatory Affairs Manager

Atlas Medical Gmbn Ludwig - Erhard Ring 3 15827 Blankenfelde - Mahlow Tel. (0049) 33708 - 355030



### GMED certifie que le système de management de la qualité développé par

GMED certifies that the quality management system developed by

## ATLAS MEDICAL GmbH Ludwig-Erhard-Ring 3 15827 Blankenfelde-Mahlow GERMANY

pour les activités for the activities

Conception et développement, fabrication et vente de dispositifs médicaux de diagnostic in vitro .

Design and Development, Manufacturing and Sales of in vitro diagnostic medical devices.

réalisées sur le(s) site(s) de performed on the location(s) of

Voir addendum

See addendum

est conforme aux exigences des normes internationales complies with the requirements of the international standards

### ISO 13485: 2016

Début de validité / Effective date October 9th, 2020 (included) Valable jusqu'au / Expiry date : October 8th, 2023 (included) Etabli le / Issued on : October 8th, 2020



ő

GMED N° 36655–1 Ce certificat est délivré selon les règles de certificatio

Ce certificat est délivré selon les règles de certification GMED / This certificate is issued according to the rules of GMED certification

ble sur Renouvelle le certificat 36655-0

**GMED** • Société par Actions Simplifiée au capital de 300 000 € • Organisme Notifié/Notified Body n° 0459 Siège social : 1, rue Gaston Boissier - 75015 Paris • Tél. : 01 40 43 37 00 • gmed.fr





Addendum au certificat n° 36655 rev. 1 page 1/1 Addendum of the certificate n° 36655 rev. 1 Dossier / File N°P601408

Ce certificat couvre les activités et les sites suivants :

This certificate covers the following activities and sites:

French version :

Conception et développement, fabrication et vente de dispositifs médicaux de diagnostic *in vitro* à usage professionnel et/ ou d'autodiagnostic, dans les domaines du groupage sanguin, de la microbiologie, de la biochimie, de la toxicologie, de l'oncologie, de la cardiologie, de l'histologie, de l'endocrinologie et des maladies infectieuses, dans les techniques d'Agglutination/ ELISA/ Tests rapides/ Colorimétrie/ Disques antibiotiques.

#### English version:

Design and Development, Manufacturing and Sales of in vitro diagnostic medical devices for professional use and/or for selftesting, in the field of Immunohematology, Microbiology, Biochemistry, Toxicology, Oncology, Cardiology, Histology, Endocrinology Biosensors and Infectious diseases, in techniques of Agglutination/ ELISA/ Rapid tests/ Colorimetry/Antibiotic disks.

#### ATLAS MEDICAL GmbH Ludwig-Erhard-Ring 3 15827 Blankenfelde-Mahlow GERMANY

French version: **Siège social, responsable de la mise sur le marché** *English version: Headquarter, legal manufacturer* 

\*\*\*\*\*

Sahab Industrial Zone Area King Abdullah II Industrial City Amman 11512 JORDAN

French version: **Conception, fabrication et contrôle final** *English version: Design, manufacture and final control* 

\*\*\*\*\*\*

William James House Cowley Road, Cambridge, CB OWX United Kingdom

French version: **Contact réglementaire** *English version: Regulatory Administration* 

\*\*\*\*\*\*

3 sites / 3 sites



On behalf of the President Béatrice LYS Technical Director



Blood Grouping Reagents: Anti-A Monoclonal Reagent, Anti-B Monoclonal Reagent, Anti-AB Monoclonal Reagent, Anti-D IgG/IgM blend Reagent, & Their variants SLIDE AND TUBE TESTS

#### IVD For In-Vitro and professional use only

2°C X Store at 2- 8°C

#### INTENDED USE

The blood grouping reagents are used to detect the presence or absence of A, B or Rhesus Antigens on the surface of human red blood cells based on hemaglutination using slide or tube test techniques in whole blood samples or anticoagulant blood samples collected in EDTA, citrate or heparin tubes.

#### INTRODUCTION & PRINCIPLES

Blood grouping reagents are prepared from In-Vitro culture supernatants of hybridized immunoglobulin-secreting mouse cell lines. The reagents are diluted with phosphate buffer containing sodium chloride, EDTA and bovine albumin to give reagents that are optimized for use in tube and slide procedures. Anti-A monoclonal reagent is colored with acid blue (patent blue) dye, Anti-B monoclonal reagent is colored with acid yellow (tartrazine) dye, and Anti-AB monoclonal reagent is not colored. The test procedure is based on hemaglutination principle, where red cells possessing the antigen agglutinate in the presence of the corresponding antibody indicating that the result is positive. The test is considered negative when no agglutination appears.

Anti-D IgG/IgM blend reagent is prepared from carefully blended human monoclonal IgM and IgG. Anti-D IgG/IgM blend reagent is suitable for slide and tube test procedures. The reagent will directly agglutinate Rh D positive cells, including majority of variants (but not D<sup>VI</sup>) and a high proportion of weak D (Du) phenotypes. The reagent will agglutinate category D<sup>VI</sup> and low grade weak D (D<sup>u</sup>) phenotypes by the indirect anti-globulin techniques.

Anti-D IgG/IgM blend reagent is diluted with a sodium chloride solution, sodium phosphate solution and bovine albumin (sodium caprylate free). Anti-D IgG/IgM blend reagent is not colored. The procedure is based on hemaglutination principle, where red cells' possessing the antigen agglutinates in the presence of the corresponding antibody in the reagent indicating that the result is positive. The test is considered negative when no agglutination appears.

#### MATERIALS

#### MATERIALS PROVIDED

Blood Grouping Reagents:

- Anti-A monoclonal reagent (10 ml/vial), Clone: (9113D10).
- Anti-B monoclonal reagent (10 ml/vial), Clone: (9621A8).
- Anti-AB monoclonal reagent (10ml/vial), Clone: (152D12+9113D10).
- Anti-D IgG/IgM Blend reagent (10 ml/vial), Clone: (P3X61 + P3X21223B10 + P3X290 + P3X35).

#### MATERIALS NEEDED BUT NOT PROVIDED

- Plastic test tube or glass.
  - Isotonic saline solution (% 0.9) NaCl).
- Applicator sticks.
- Centrifuge (100-1200 (g) for tube test).
- Timer.
- Incubator
- Anti-Human Globulin Reagent (can be ordered from Atlas Medical).
- White or transparent glass slide.

#### PRECAUTIONS

- The reagents are intended for in vitro diagnostic use only.
- The test is for well trained professional healthy user not for lay user.
- These reagents are derived from animal and human sources, thus, appropriate care must be taken in the use and disposal of these reagents, as there are no known test methods that can guarantee absence of infectious agents.
- Do not use reagents if it is turbid or contain particles as this may indicate reagent deterioration or contamination.
- Protective clothing should be worn when handling the reagents.
- The reagents contain (0.1-0.2%) Sodium Azide and 0.02% sodium arseniate which is toxic and can be absorbed through the skin. When drained, the drains should be thoroughly flushed with water.
- The reagents should be used as supplied and in accordance to the procedure mentioned below. Don't use beyond expiration date.
- Avoid cross contamination of reagents or specimens.
- Visible signs of microbial growth in any reagent may indicate degradation and the use of such reagent should be discontinued.

- Don't use these reagents if the label is not available or damaged.
- Do not use dark glass slide.
  - Don't use the kit if damaged or the glass vials are broken or leaking and discard the contents immediately.
- Test materials and samples should be discarded properly in a biohazard container.
- Wash hands and the test table top with water and soap once the testing is done.
- Heamolysed blood sample should not be used for testing.
- The test should be performed at room temperature in a well let area with very good visibility.
- Failure to follow the procedure in this package insert may give false results or safety hazard.
- Close the vial tightly after each test.
- The reagent is considered toxic, so don't drink or eat beside it.
- If spillage of reagent occurs clean with disinfectant (disinfectant used could be irritable so handle with care).

#### STORAGE CONDITIONS

- The reagents should be stored refrigerated between 2 8°C.
- Never Freeze or expose to elevated temperature.
- The reagent is stable until the expiry date stated on the product label. Do not use the reagents past the expiry date.

#### REAGENT PREPRATION

- The reagents are intended for use as supplied, no prior preparation or dilution of the reagent is required.
- All reagents should be brought to room temperature before use.

#### SPECIMEN COLLECTION AND PREPARATION

• Blood collected with or without anticoagulant (EDTA, Heparin or Citrate) can be used for Antigen typing.

Note: Blood collected without anticoagulant should be tested immediately.

- The specimens should be tested as soon as possible after collection. If testing is delayed, the specimens should be stored at 2- 8 °C, Sample must be retained to room temperature prior to analysis. (Testing should be carried out within five days of collections).
- Insure that there is no sign of hemolysis.
- At the time of the test, centrifuge the blood sample at 1200 RCF for 3 minutes.
- Blood collection is to be done with great care.

#### PROCEDURES

- A. DIRECT TUBE METHOD AT ROOM TEMPERATURE
  - 1. Prepare a 5% suspension of red blood cells in isotonic solution.
  - 2. Using the vial dropper, transfer a drop ( $40\pm10\mu$ I) of each reagent into a separate and appropriately marked tube.
  - 3. Add 50 µl of red blood cell suspension prepared in step 1.
  - Shake to homogenize the mixture, then centrifuge at 500g for 1 minute.
  - Gently shake the tube in such a way to detach the cell pellet and macroscopically observe for any possible agglutination.
  - 6. Read the reaction immediately.
  - For Anti-D tube, if the reaction is weak or negative, shake the tubes and incubate at 37°C for 15 minutes.
  - Wash the red blood cells twice with isotonic saline solution (NaCl 0.9%) and discard the last washing liquid.
  - 9. Add one drop (50 $\mu$ l) of the AHG reagent into the tube. Mix and centrifuge at 120g for  $1\mbox{ minute.}$
  - 10. Gently shake the tube in such a way to detach the cell pellet and macroscopically observe for any possible agglutination.

#### 11. Read the reaction immediately. B. ANTIGLOBULIN INDIRECT METHOD for ANTI-D

- After immediately centrifuging and reading as above, if the reaction is weak or negative, shake the tubes and incubate at 37°C for 15 minutes.
- Wash the red blood cells twice with isotonic saline solution (NaCl 0.9%) and discard the last washing liquid.
- 3. Add one drop (40  $\mu l$   $\pm$  10  $\mu l)$  of ANTI-HUMAN GLOBULIN to the tube. Mix and centrifuge at 120 (g) for 1 minute.
- Gently shake the tube in such a way to detach the cell pellet and macroscopically observe for any possible agglutination.

#### Read the reaction immediately.

#### C. DIRECT SLIDE METHOD AT ROOM TEMPERATURE

- 1. Bring reagents and samples to room temperature (18-25°C).
- 2. Using the wax pen divide the slide into appropriate numbers of divisions.
- 3. Using the provided dropper, place one drop (40  $\mu l$   $\pm$  10  $\mu l)$  of each reagent onto its correspondent division on the slide.
- 4. Add 25µl of the precipitated cells next to each drop of reagents.
- 5. Mix the reagent and the cells using a clean stirring stick over an
- area with a diameter of approximately 20-40mm.
  6. Incubate the slide at room temperature (18-25°C) without stirring for 30 seconds.
- Hold the slide and gently rock the slide for 3 minutes and observe macroscopically for any agglutination.
- 8. Read the reaction immediately.

#### READING THE RESULT <u>POSITIVE</u>: If Agglutination appears. <u>NEGATIVE</u>: If no agglutination is observed. Use the below table to determine the blood group:

	Result of e	ach reaction		
Anti-A monoclonal reagent	Anti-B monoclonal reagent	Anti-AB monoclonal reagent	Anti-D IgG/IgM blend reagent	ABO Group
+	-	+	+	A+
+	-	+	-	A-
-	+	+	+	B+
-	+	+	-	В-
+	+	+	+	AB+
+	+	+	-	AB-
-	-	-	+	0+
-	-	-		0-

#### STABILITY OF THE REACTIONS

- ABO Blood Grouping Tube tests should be read immediately following centrifugation.
- Slide tests should be interpreted within three minutes to avoid the possibility that a negative result may be incorrectly interpreted as positive due to drying of reagents.
- Delay in reading and interpreting results may result in weekly positive or falsely negative reactions. Slide tests should be interpreted at the end of the three minutes.

#### PROCEDURE LIMITATION

1. False positive/ negative results may occur due to:

- Contamination from test materials.
- Improper storage, cells concentration, incubation time or temperature.
- Improper or excessive centrifugation.
- Deviation from the recommended technique.
- Blood samples of weak A or B subgroups may give rise to false negative results or weak reactions when tested using slide test method. It is advisable to re-test weak subgroups using tube test method.
- 2. Weaker reactions may be observed with stored blood than with fresh blood.
- 3. ABO antigens are not fully developed at birth, weaker reactions may therefore occur with cord or neonatal red cells.
- 4. ABO blood grouping interpretation on individuals greater than 6 months old should be confirmed by testing serum or plasma of the individual against group A and group B red cells (reverse grouping). If the results obtained with the serum do not correlate with the red cell test, further investigation is required.
- 5. Return the kit to the agent if it does not function properly.
- Anti-D IgG/IgM blend Reagent tests conducted on particular weak-D phenotypes, while satisfactory, cannot ensure recognition of all weak variants, due to the variability of antigen patterns.

#### DIAGNOSTIC PERFORMANCE CHARACTERISTICS

The following tables compare the results in slide and tube techniques of 3 lots of Atlas Medical reagents and the results of a CE marked device.

Slide Technique				
Group A				
Positive with anti-A monoclonal reagent and anti-AB monoclonal reagent Negative with anti-B and Negative control				
CE marked device	Lot A	Lot B	Lot C	Compliance
232	232	232	232	100%
	Tube	Technique		
Group A				
Positive with	Positive with anti-A monoclonal reagent and anti-AB			
monoclonal reagent Negative with anti-B and Negative control				
Negativ	e with anti	-B and Neg	ative contr	ol
Negativ CE marked device	e with anti	-B and Neg	ative contr	Compliance
Negativ CE marked device 212	e with anti	-B and Neg	ative contr	loo Compliance 100%
Negativ CE marked device 212	e with anti	-B and Neg	ative contr	ol Compliance 100%



CE marked device	Lot A	Lot B	Lot C	Compliance
61	61	61	61	100%
	Tube	Technique		
	G	iroup B		
Positive with anti-B monoclonal reagent and anti-AB monoclonal reagent Negative with anti-A and Negative control				
CE marked device	Lot B	Lot C	Compliance	
61	61	61	61	100%

Slide Technique					
Group O					
Negative with anti-A monoclonal reagent, Anti-B				Anti-B reagent	
Ne	egative wit	h Negative	control	0	
CE marked device	Lot A	Lot B	Lot C	Compliance	
241	241	241	241	100%	
Tube Technique					
Group O					
Negative with anti-A monoclonal reagent, Anti-B monoclonal reagent and anti-AB monoclonal reagent Negative with Negative control					
CE marked E CE marked E CE marked E CE marked E CE CE marked E CE C				Compliance	
243	243 243 243 243 100%				

Slide Technique				
	Group AB			
Positive w	ith anti-A n	nonoclona	l reagent, A	Anti-B
monoclonal r	eagent and	l anti-AB n	nonoclonal	reagent
Ne	egative wit	n Negative	control	-
CE marked device	Lot A	Lot B	Lot C	Compliance
33	33	33	33	100%
Tube Technique				
Group AB				
Positive w	ith anti-A n	nonoclona	l reagent, A	Anti-B
monoclonal r	eagent and	l anti-AB n	nonoclonal	reagent
Negative with Negative control				
CE marked V CE POINT CE POI				Compliance
24	24	24	24	100%

No inversion in diagnosis has been shown: from a qualitative point of view we have observed 100% compliance in direct group testing in slide and tube techniques for determination of A, B, AB and O groups for the three lots of Atlas Medical.

#### QUALITY CONTROL

The reactivity of all blood grouping reagents should be confirmed by testing known positive and negative red blood cells on each day of use. To confirm the specificity and sensitivity, Blood grouping reagents should be tested with antigen-positive and antigen-negative red blood cells.

#### REFERENCES

- BCSH Blood Transfusion Task Force. Guidlines for microplate techniques in liquid-phase blood grouping and antibody screening. Clin. Lab. Haem 1990: 12, 437-460.
- Issitt P. D. Applied Blood Group Serology, 3rd ed. Miami: Montgomery Scientific, 1985.
- Kholer G., Milstein C. Continuous culture of fused cells secreting antibody of predefined specificity, 256, 495-497, 1975
- Messeter L. et. al. Mouse monoclonal antibodies with anti-A, anti-B and anti-A,B specificities, some superior to human polyclonal ABO reagents, Vox Sang 46, 185-194, 1984
- Race R.R. and Sanger R. Blood groups in man, 6th ed., Oxford: Blackwell Scientific, 1975.
- 6. Voak D. ET. al., Monoclonal anti-A and anti-B development as cost effective reagents. Med. Lab. Sci 39, 109-122. 1982.

- 7. Standards for Blood Banks d Transfusion Service. 11th Ed., Washington D.C., AABB 1984:25.
- 8. Widmann F.K.ed Technical Manual, 9th Ed., Wahington D.C.: AABB 1985:9.

Atlas Medical GmbH Ludwig-Erhard-Ring 3 15827 Blankenfelde-Mahlow Germany Tel: +49 - 33708 - 3550 30 Email: Info@atlas-medical.com Website: www.atlas-medical.com

PPI861A01 Rev.L (19.02.2022)



LIST OF VARIENTS	S:
Product Code	Product Name
8.02.00.0.0010	Anti-A Monoclonal Reagent (Titer: 1 /512), 10ml/vial, 1 vial/Carton Box
8.02.00.1.0100	Anti-A Monoclonal Reagent (Titer: 1 /512), 10ml/vial. 10 vials / Plastic Pack
8.02.00.1.0180	Anti-A Monoclonal Reagent (Titer: 1 /512), 10ml/vial. 18 vials / Carton Box
8.02.01.0.0010	Anti-B Monoclonal Reagent (Titer: 1 /512), 10ml/vial, / Carton Box
8.02.01.1.0100	Anti-B Monoclonal Reagent (Titer: 1 /512), 10ml/vial, 10 vials / Plastic Pack
8.02.01.1.0180	Anti-B Monoclonal Reagent (Titer: 1 /512), 10ml/vial, 18 vials / Carton Box
8.02.02.0.0010	Anti-AB Monoclonal Reagent (Titer: 1 /512), 10ml/vial, 1 vial/ Carton Box
8.02.02.1.0100	Anti-AB Monoclonal Reagent (Titer: 1 /512), 10ml/vial, 10 vials/Plastic Pack
8.02.02.1.0180	Anti-AB Monoclonal Reagent (Titer: 1 /512), 10ml/vial, 18 vials/Carton Box
8.02.03.0.0010	Anti-D IgG/IgM Blend Reagent (Titer: 1 /128), 10ml/vial, 1 vial/ Carton Box
8.02.03.1.0100	Anti-D IgG/IgM Blend Reagent (Titer: 1 /128), 10ml/vial, 10 vials / Plastic Pack
8.02.03.1.0180	Anti-D IgG/IgM Blend Reagent (Titer: 1 /128), 10ml/vial, 18 vials / Carton Box
8.02.04.0.0010	Anti-A Monoclonal Reagent (Titer: 1 /256), 10ml/vial, 1 Vial/Carton Box
8.02.04.0.0100	Anti-A Monoclonal Reagent (Titer: 1 /256), 10ml/vial, 10 vials / Plastic Pack
8.02.05.0.0010	Anti-B Monoclonal Reagent (Titer: 1 /256), 10ml/vial, 1vial/Carton Box
8.02.05.0.0100	Anti-B Monoclonal Reagent (Titer: 1 /256), 10ml/vial, 10 vials /Plastic Pack
8.02.05.6.0030	ABO Set (Anti-A (1/256), Anti-B (1 /256), Anti-D (1/64)),3x10ml / plastic Pack
8.02.05.7.0020	ABO Set: Anti-A (1/256), Anti-B (1 /256), 2x10ml /Plastic Pack
8.02.06.0.0010	Anti-AB Monoclonal Reagent (Titer: 1 /256), 10ml/vial, 1vial/Carton Box
8.02.06.1.0100	Anti-AB Monoclonal Reagent (Titer: 1 /256), 10ml/vial,10 vials /Plastic Pack
8.02.06.1.0180	Anti-AB Monoclonal Reagent (Titer: 1 /256), 10ml/vial,18 vials / Carton Box
8.02.07.0.0010	Anti-D IgG/IgM Blend Reagent (Titer: 1 /64), 10ml/vial, 1Vial/ Carton Box
8.02.07.1.0100	Anti-D IgG/IgM Blend Reagent (Titer: 1 /64), 10ml/vial, 10 vials / Plastic Pack
8.02.47.0.0030	ABO Set (Anti-A (1 /512), Anti-B (1 /512), Anti-D (1 /128)),3x10ml/Plastic Pack
8.02.47.1.0030	ABO Set (Anti-A (1 /256), Anti-B (1 /256), Anti-D (1 /64)), 3x10ml /Carton Box.
8.02.47.3.0030	ABO Set (Anti-A (1 /256), Anti-B (1 /256), Anti-D (1 /64)), 3x10ml /Plastic Pack
8.02.47.5.0030	ABO Set (Anti-A (1 /256), Anti-B (1 /256), Anti-D (1 /128)), 3x10ml/Plastic Pack
8.02.49.0.0040	ABO Set (Anti-A (1 /256), Anti-B (1 /256), Anti-AB (1 /256), Anti-D (1 /64)), 4x10ml/Carton Box
8.02.49.2.0040	ABO Set (Anti-A (1 /256), Anti-B (1 /256), Anti-AB (1 /256), Anti-D (1 /128)), 4 x 10ml, 4 vials/Plastic Pack
8.02.53.0.0040	ABO Set (Anti-A (1 /512), Anti-B (1 /512), Anti-AB (1 /512) Anti-D (1 /128)), 4x10ml/Plastic Pack
8.02.53.1.0040	ABO Set (Anti-A (1 /512), Anti-B (1 /512), Anti-AB (1 /512) Anti-D (1 /128)), 4x10ml, 4vials/Plastic Pack
8.02.70.0.0010	Anti-A monoclonal reagent , Titer (1/1024), 10 ml/vial, 1Vial/ Carton Box
8.02.71.0.0010	Anti-B Monoclonal reagent (Titer: 1 /1024), 10 ml/vial, 1Vial/Carton Box
8.02.72.0.0010	Anti-AB Monoclonal reagent (Titer: 1 /1024) , 10 ml/vial , 1Vial/ Carton Box
8.02.85.0.0010	Anti-D IgG/IgM Blend reagent ( Titer 1 /256), 10ml/vial, 1Vial/ Carton Box

REF	Catalogue Number		Temperature limit
IVD	In Vitro diagnostic medical device	$\wedge$	Caution
V	Contains sufficient for <n> tests and Relative size</n>	<b>i</b>	Consult instructions for use (IFU)
LOT	Batch code		Manufacturer
Ţ	Fragile, handle with care		Use-by date
	Manufacturer fax number	8	Do not use if package is damaged
	Manufacturer telephone number	~	Date of Manufacture
漛	Keep away from sunlight	Ť	Keep dry



# STATEMENT

We, DIALAB Produktion und Vertrieb von chemisch-technischen Produkten und Laborinstrumenten Gesellschaft m.b.H., having a registered office at IZ-NOE Sued Hondastrasse, Objekt M55, A-2351 Wr. Neudorf, AUSTRIA assign SRL SANMEDICO having a registered office at A. Corobceanu street 7A, apt. 9, Chişinău MD-2012, Moldova, as authorized representative in correspondence with the conditions of directive 98/79/EEC. We declare that the company mentioned above is authorized to register, notify, renew or modify the registration of medical devices on the territory of the Republic of Moldova. This declaration will stay in force for 2 years or if one of the parties is deciding to cancel it with a one-month notice.

Date :05.04.2023 Signature:



Christina Ernst Export Manager

DIALAB Produktion und Vertrieb von chemisch-technischen Produkten und Laborinstrumonten Gesellschaft m.b.M. IZ-NDE Suad Hondastrasse, Objeki ½55 2351 WR. NEUDORF AUSTRIA Phone: +43(0)2236 660910-0 Fax: +43(0)2236 660910-30 Mail: office@dialsb.at www.dialsb.at Managing Director | Geschäftsführer Murat Estelik, Dipl. Ing. Martene Ramsey FN 108 078p | Landesgericht Wr. Naustadt UID/YAT: ATU 150 136 06 | DVR: 0130885 
 Bic / SWHT:
 RLNWATWWGTD

 ISAN 6:
 AT97 3225 0000 0070 6739

 IBAN USD:
 AT52 3225 0301 0070 6739

## EC DECLARATION OF CONFORMITY

EG-KONFORMITÄTSERKLÄRUNG





Dialab Produktion und Vertrieb von

chemisch-technischen Produkten und Laborinstrumenten Gesellschaft m.b.H. IZ-NOE Sued, Hondastrasse, Objekt M55, A-2351 Wiener Neudorf

REF

Z12360

Product Name / Produktname

96 wells

Content / Inhalt

Lot Numbers / Lotnummern: B20220401, B20220601, B20221001

**HBsAg Sensitive ELISA** 

Notified Body / Benannte Stelle:

bqs. s.r.o., NB no. 2854, Študentská 1641/12, 911 01 Trenčín, Slovakia

No. CE Certificate / Nr. CE-Zertifikat: IVDD 22 004 0137, IVDD 22 004 0138

We declare, on our own responsibility, that our above-mentioned product classified as follows according to the directive on in vitro diagnostic medical devices 98/79/EC: **Devices of List A, Annex II** 

meets the applicable provisions of the EU Directive 98/79/EC for in-vitro-diagnostic medical devices and the Austrian Medical Product Law.

The following (harmonized) standards have been applied: EN ISO 18113-1:2011, EN ISO 18113-2:2011, EN ISO 15223-1: 2016, EN 13612: 2002, EN ISO 23640:2015, EN 13641:2002, EN ISO 14971:2019, EN ISO 13485:2016 and CTS.

The product is in compliance with common technical specifications as they are defined within Commission Decision (2009/886/EC) of 27 November 2009 amending Decision 002/364/EC on common technical specifications for in vitro diagnostic medical devices.

This Declaration is based on approval according to Annex IV of the aforesaid Directive in cooperation with above mentioned notified body

Technical documentation demonstrating compliance is kept by the manufacturer and can be made available.

This Declaration is valid until 2025-03-28.

Hiermit erklären wir, auf eigene Verantwortung, dass unser oben genanntes Produkt, gemäß der Richtlinie 98/79/EG über In-vitro-Diagnostika klassifiziert als: **Produkte der Liste A, Anhang II** 

die anwendbaren Vorschriften der EU-Richtlinie 98/79/EG über in-Vitro-Diagnostika und des Österreichischen Medizinproduktegesetzes erfüllt.

Die folgenden (harmonisierten) Standards wurden angewandt: EN ISO 18113-1:2011, EN ISO 18113-2:2011, EN ISO 15223-1: 2016, EN 13612: 2002, EN ISO 23640:2015, EN 13641:2002, EN ISO 14971:2019, EN ISO 13485:2016 und CTS.

Das Produkt entspricht den Gemeinsamen Technischen Spezifikationen wie diese in der Entscheidung der Kommission vom 27. November 2009 (2009/886/EG) zur Änderung der Entscheidung 2002/364/EG über Gemeinsame Technische Spezifikationen für In-vitro-Diagnostika definiert sind.

Diese Erklärung basiert auf Freigabe gemäß Anhang IV der oben angeführten Richtlinie in Zusammenarbeit mit oben genannter Benannter Stelle.

Die Technische Dokumentation zum Nachweis der Konformität wird vom Hersteller aufbewahrt und kann zur Verfügung gestellt werden.

Diese Erklärung ist bis zum 2025-03-28 gültig.

.ktion und Vertrieb von chemisch - technischen .dukten und Laborinstrumenten Gesellschaft m.b.H. 2351 Wr. Neudorf, IZ-NŐ Süd, Hondastr. Obj.M55 trong: ++43 (0) 2236 660910 - 0 Fax ++43 (0) 2236 660910 - 30 L Mail: office Odalab.at \_\_\_\_\_Website: www.dialab ;

Heidi Kroiß

Qualitätsmanagementbeauftragte Quality Management Representative

on

Wiener Neudorf, 2022-01-30

DIALAB Produktion und Vertrieb von chemisch-technischen Produkten und Laborinstrumenten Gesellschaft m.b.H. IZ-NOE Sued Hondastrasse, Objekt M55 2351 WR. NEUDORF AUSTRIA Phone: +43(0)2236 660910-0 Fax: +43(0)2236 660910-30 Mail: office@diatab.at www.diatab.at Managing Director | Geschäftsführer Murat Estelik, Dipl. Ing. Marlene Ramsey FN 108 078p | Landesgericht Wr. Neustadt UID/VAT: ATU 150 136 06 { DVR: 0130885 
 Raiffeisen Regionalbank Moedling

 BIC / SWIFT:
 RLNWATWWGTD

 IBAN €:
 AT97 3225 0000 0070 6739

 IBAN USD:
 AT52 3225 0301 0070 6739







# Certificate

No. Q5 026709 0009 Rev. 01

### Holder of Certificate:

### **DIALAB Produktion und Vertrieb von** chemisch-technischen Produkten und Laborinstrumenten Gesellschaft m.b.H.

**IZ-NOE** Sued Hondastrasse, Objekt M55 2351 Wr. Neudorf **AUSTRIA** 

### **Certification Mark:**



## Scope of Certificate:

Design, development, production and distribution of in-vitro diagnostic reagents and testkits in the areas of immunological detection of infectious diseases, immunochemistry/immunology/clinical chemistry biomarkers (analytes: enzymes, substrates, electrolytes reagents; controls/standards/calibrators), urinalysis, haematology, haemostasis and immunohaematology (blood grouping). Distribution of in-vitro diagnostic instruments including accessories for immunology, clinical chemistry, haematology, haemostasis and urinalysis.

The Certification Body of TÜV SÜD Product Service GmbH certifies that the company mentioned above has established and is maintaining a quality management system, which meets the requirements of the listed standard(s). All applicable requirements of the testing and certification regulation of TÜV SÜD Group have to be complied with. For details and certificate validity see: www.tuvsud.com/ps-cert?q=cert:Q5 026709 0009 Rev. 01

Report No.:

713237224

Valid from: Valid until: 2022-03-29

2025-03-28

Date, 2022-03-17

Christoph Dicks Head of Certification/Notified Body





# Certificate

No. Q5 026709 0009 Rev. 01

Applied Standard(s):	EN ISO 13485:2016 Medical devices - Quality management systems - Requirements for regulatory purposes (ISO 13485:2016) DIN EN ISO 13485:2016

Facility(ies):DIALAB Produktion und Vertrieb von chemisch-technischen<br/>Produkten und Laborinstrumenten Gesellschaft m.b.H.<br/>IZ-NOE Sued, Hondastrasse, Objekt M55, 2351 Wr. Neudorf,<br/>AUSTRIA

See Scope of Certificate

### Parameters: ./.



DIALAB Produktion und Vertrieb von chemisch-technischen Produkten und Laborinstrumenten Gesellschaft m.b.H. IZ NOE-Sued, Hondastrasse, Objekt M55, 2351 Wr. Neudorf, Austria Phone: +43 (0) 2236 660910-0, Fax: +43 (0) 2236 660910-30, e-mail: <u>office@dialab.at</u>

# **HBsAg Sensitive ELISA**

(en) English



### Content

- 1 Microwell Plate: 96 wells (12x 8-well antibody coated strips, individual breakaway)

- 1x 1 mL Positive Control
- 1x 1 mL Negative Control
- 1x 6 mL Enzyme Conjugate
- 1x 5 mL Specimen Diluent
- 1x 6 mL Substrate Solution A
- 1x 6 mL Substrate Solution B
- 1x 6 mL Stop Solution
- 1x 30 mL Wash Buffer
- 3 Cardboard Plate Covers
- 1 Plastic Bag
- 1 Package Insert
- 1 Certificate of Analysis

### For professional in vitro diagnostic use only.

#### **INTENDED USE**

HBsAg Sensitive ELISA is an enzyme-linked immunosorbent assay (ELISA) for the qualitative detection of Hepatitis B surface antigen (HBsAg) in human serum or plasma. It is intended for the screening of blood donors and for the diagnosis of patients related to infection with Hepatitis B virus.

### **DIAGNOSTIC SIGNIFICANCE**

Hepatitis B virus (HBV) is an enveloped, double-stranded DNA virus belonging to the *Hepadnaviridae* family and is recognized as the major cause of blood transmitted hepatitis together with hepatitis C virus (HCV). Infection with HBV induces a spectrum of clinical manifestations ranging from mild, unapparent disease to fulminant hepatitis, severe chronic liver diseases, which in some cases can lead to cirrhosis and carcinoma of the liver. Classification of a hepatitis B infection requires the identification of several serological markers expressed during three phases (incubation, acute and convalescent) of the infection. Now several diagnostic tests are used for screening, clinical diagnosis and management of the disease. Hepatitis B surface antigen or HBsAg, previously described as Australia antigen, is the most important protein of the envelope of Hepatitis B Virus. The surface antigen contains the determinant "a", common to all known viral subtypes and immunologically distinguished in two distinct subgroups (ay and ad). HBV has 10 major serotypes and four HBsAg subtypes have been recognized (adw, ady, ayw, and ayr). HBsAg can be detected 2 to 4 weeks before the ALT levels become abnormal and 3 to 5 weeks before symptoms develop. The serological detection of HBsAg is a powerful method for the diagnosis and prevention of HBV infection and ELISA has become an extensively used analytical system for screening of blood donors and clinical diagnosis of HBV in infected individuals.

### TEST PRINCIPLE

For detection of HBsAg, Dialab HBsAg Sensitive ELISA uses antibody "sandwich" ELISA method, in which, polystyrene microwell strips are pre-coated with monoclonal antibodies specific to HBsAg. Patient's serum or plasma sample is added to the microwells. During incubation, the specific immunocomplex formed in case of presence of HBsAg in the sample, is captured on the solid phase. Then the second antibody conjugated the enzyme horseradish peroxidase (the Enzyme Conjugate) directed against a different epitope of HBsAg is added into the wells. During the second incubation step, these HRP-conjugated antibodies will be bound to any anti-HBs-HBsAg complexes previously formed during the first incubation, and the unbound HRP-conjugate is then removed by washing. After washing to remove unbound HRP-conjugate, Chromogen solutions containing tetramethyl-benzidine (TMB) and urea peroxide are added to the wells. In presence of the antibody-antigen-antibody (HRP) "sandwich" immunocomplex, the colorless Chromogens are hydrolyzed by the bound HRP-conjugate to a blue-colored product. The blue color turns yellow after stopping the reaction with sulfuric acid. The amount of color intensity can be measured and it is proportional to the amount of antigen captured in the wells, and to its amount in the sample respectively. Wells containing samples negative for HBsAg remain colorless.

### **REAGENT COMPOSITION**

Component	Description
	Blank microwell strips fixed on white strip holder. The plate is sealed in aluminum pouch with
Microwell plate	desiccant. 12x 8-well strips per plate. Each well contains monoclonal antibodies reactive to
	HBsAg (anti-HBs). The microwell strips can be broken to be used separately. Place unused



	wells or strips in the plastic sealable storage bag together with the desiccant and return to 2- 8°C.
	Once open, stable for 4 weeks at 2-8°C.
Positive Control	Red-colored liquid filled in a vial with red screw cap. HBsAg diluted in protein-stabilized buffer. Ready to use as supplied. Contains 0.1% ProClin <sup>™</sup> 300 as preservative. <b>Once open, stable for 4 weeks at 2-8°C.</b>
Negative Control	Yellowish liquid filled in a vial with green screw cap. Protein-stabilized buffer tested non-reactive for HBsAg. Ready to use as supplied. Contains 0.1% ProClin <sup>™</sup> 300 as preservative. <b>Once open, stable for 4 weeks at 2-8°C.</b>
Enzyme Conjugate	Red-colored liquid filled in a vial with red screw cap. Horseradish peroxidase conjugated anti HBs antibodies. Ready to use as supplied. Contains 0.1% ProClin <sup>™</sup> 300 as preservative. <b>Once open, stable for 4 weeks at 2-8°C.</b>
Specimen Diluent	Green-colored liquid in a vial with blue screw cap. Buffer Solution containing protein. Ready to use as supplied. Contains 0.1% ProClin <sup>™</sup> 300 as preservative. <b>Once open, stable for 4 weeks at 2-8°C.</b>
Substrate Solution A	Colorless liquid filled in a white vial with green screw cap. Urea peroxide solution. Ready to use as supplied. Once opened, stable for 4 weeks at 2-8°C.
Substrate Solution B	Colorless liquid filled in a black vial with black screw cap. TMB (Tetramethyl benzidine), N,N- dimethylformamide. Ready to use as supplied. <b>Once opened, stable for 4 weeks at 2-8°C.</b>
Stop Solution	Colorless liquid in a white vial with yellow screw cap. Diluted sulfuric acid solution (0.5 M H <sub>2</sub> SO <sub>4</sub> ). Ready to use as supplied. <b>Once opened, stable for 4 weeks at 2-8°C.</b>
Wash Buffer	Colorless liquid filled in a clear bottle with white screw cap, pH 7.4, 20x PBS. The concentrate must be diluted <b>1 to 20</b> with distilled/ deionized water before use. Contains Tween 20 as a detergent. <b>Once diluted, stable for one week at room temperature, or for two weeks when stored at 2-8°C.</b>

#### MATERIAL REQUIRED BUT NOT PROVIDED

- Freshly distilled or deionized water
- Disposable gloves and timer
- Appropriate waste containers for potentially contaminated materials
- Dispensing system and/or pipette
- Disposable pipette tips
- Absorbent tissue or clean towel
- Dry incubator or water bath 37 ± 1°C
- Plate reader, single wavelength 450 nm or dual wavelength 450/600-650 nm
- Microwell aspiration/wash system

### **REAGENT PREPARATION**

Allow the reagents and samples to reach room temperature (18-30°C) for at least 15-30 minutes. Check the Wash Buffer concentrate for the presence of salt crystals. If crystals have formed, resolubilize by warming at 37°C until crystals dissolve. Dilute the Wash Buffer 1:20 as indicated in the instructions for washing. Use distilled or deionized water and only clean vessels to dilute the buffer. All other reagents are ready to use as supplied.

#### STORAGE AND STABILITY

The components of the kit will remain stable through the expiration date indicated on the label and package when stored between 2-8°C, do not freeze. To assure maximum performance of this HBsAg Sensitive ELISA kit, during storage protect the reagents from contamination with microorganisms or chemicals.

### WARNINGS AND PRECAUTIONS

Warning:

#### ProClin<sup>™</sup> 300:



- H317: May cause an allergic skin reaction.
- H412: Harmful to aquatic life with long lasting effects
- P273: Avoid release to the environment
  - P280: Wear protective gloves/protective clothing/eye protection/face protection.

P333+313: If skin irritation or rash occurs: Get medical advice/attention.

P363: Wash contaminated clothing before reuse.



#### N,N dimethylformamide:



Danger: H360D: May damage the unborn child. P201: Obtain special instruction before use. P280: Wear protective gloves/protective clothing/eye protection/face protection. P308+P313: If exposed or concerned: Get medical advice/attention.

#### TO BE USED ONLY BY QUALIFIED PROFESSIONALS.

The ELISA assay is a time and temperature sensitive method. To avoid incorrect results, **strictly follow the test procedure steps and do not modify them.** 

- Do not exchange reagents from different lots, or use reagents from other commercially available kits. The components of the kit are precisely matched as to achieve optimal performance of the test.
- Make sure that all reagents are within the validity indicated on the kit box and are of the same lot. Never use reagents beyond the expiry date stated on labels or boxes.
- CAUTION CRITICAL STEP: Allow the reagents and samples to reach room temperature (18-30°C) before use. Shake reagent gently before use. Return to 2-8°C immediately after use.
- Use only sufficient volume of sample as indicated in the procedure steps. Failure to do so may cause in low sensitivity of the assay.
- Do not touch the bottom exterior of the wells; fingerprints or scratches may interfere with microwell reading. When reading the results, ensure that the plate bottom is dry and there are no air bubbles inside the wells.
- Never allow the microplate wells to dry after the washing step. Immediately proceed to the next step. Avoid the formation of air-bubbles when adding the reagents.
- Avoid assay steps long time interruptions. Assure same working conditions for all wells.
- Calibrate the pipette frequently to assure the accuracy of samples/reagents dispensing. Use different disposal pipette tips for each specimen and reagents as to avoid cross-contamination.
- Assure that the incubation temperature is 37°C inside the incubator.
- When adding samples, avoid touching the well's bottom with the pipette tip.
- When measuring with a plate reader, determine the absorbance at 450 nm or 450/600-650 nm.
- The enzymatic activity of the Enzyme Conjugate might be affected by dust, reactive chemicals, and substances like sodium hypochlorite, acids, alkalis etc. Do not perform the assay in the presence of such substances.
- If using fully automated equipment, during incubation, do not cover the plates with the plate cover. The tapping out of the remainders inside the plate after washing, can also be omitted.
- All specimens from human origin should be considered as potentially infectious. Strict adherence to GLP (Good Laboratory Practice) regulations can ensure the personal safety.
- WARNING: Materials from human origin have been used in the preparation of the Negative Control in the kit. These materials have been tested with test kits with accepted performance and found negative for antibodies to HIV 1&2, HCV, TP and HBsAg. However, there is no analytical method that can assure that infectious agents in the specimens or reagents are completely absent. Therefore, handle reagents and specimens with extreme caution as if capable of transmitting infectious diseases. Bovine derived sera have been used for stabilizing of the positive and negative controls. Bovine serum albumin (BSA) and fetal calf sera (FCS) are derived from animals from BSE/TSE-free geographical areas.
- Never eat, drink, smoke, or apply cosmetics in the assay laboratory. Never pipette solutions by mouth.
- Chemicals should be handled and disposed of only in accordance with the current GLP (Good Laboratory Practices) and the local or national regulations.
- The pipette tips, vials, strips and sample containers should be collected and autoclaved for 2 hours at 121°C or treated with 10% sodium hypochlorite for 30 minutes to decontaminate before any further steps for disposal. Solutions containing sodium hypochlorite should NEVER be autoclaved.
- Materials Safety Data Sheet (MSDS) available upon request.
- Some reagents may cause toxicity, irritation, burns or have carcinogenic effect as raw materials. Contact with the skin and the mucosa should be avoided but not limited to the following reagents: Stop Solution, the Substrate Solutions and the Wash buffer.
- The Stop Solution (0.5 M H<sub>2</sub>SO<sub>4</sub>) is an acid. Corrosive. Use it with appropriate care. Wipe up spills immediately or wash with water if come into contact with the skin or eyes.
- ProClin™300 0.1% used as a preservative can cause sensation of the skin. Wipe up spills immediately or wash with water if come into contact with the skin or eyes.

#### Indications of Instability or Deterioration of the Reagent:

Values of the Positive or Negative controls, which are out of the indicated quality control range, are indicators of possible deterioration of the reagents and/or operator or equipment errors. In such case, the results should be



considered as invalid and the samples must be retested. In case of constant erroneous results and proven deterioration or instability of the reagents, immediately substitute the reagents with new one or contact Dialab for further assistance.

### SPECIMEN COLLECTION AND STORAGE

- Sample Collection: No special patient's preparation required. Collect the specimen in accordance with the normal laboratory practice. Either fresh serum or plasma specimens can be used with this assay. Blood collected by venipuncture should be allowed to clot naturally and completely the serum/plasma must be separated from the clot as early as possible as to avoid haemolysis of the RBC. Care should be taken to ensure that the serum specimens are clear and not contaminated by microorganisms. Any visible particulate matters in the specimen should be removed by centrifugation at 3000 RPM (round per minutes) for 20 minutes at room temperature or by filtration.
- Plasma specimens collected into EDTA, sodium citrate or heparin may be tested, **but highly lipaemic, icteric, or** haemolytic specimens should not be used as they can give false results in the assay. Do not heat inactivate specimens. This can cause deterioration of the target analyte. Samples with visible microbial contamination should never be used.
- Dialab HBsAg Sensitive ELISA is intended ONLY for testing of individual serum or plasma samples. Do not use the assay for testing of cadaver samples, saliva, urine or other body fluids or pooled (mixed) blood.
- **Transportation and Storage**: Store specimens at 2-8°C. Specimens not required for assaying within 7 days should be stored frozen (-20°C or lower). Multiple freeze-thaw cycles should be avoided. For shipment, samples should be packaged and labelled in accordance with the existing local and international regulations for transportation of clinical samples and ethological agents.

### **TEST PROCEDURE**

- 1. **Preparation**: Mark three wells as Negative control (e.g. B1, C1, D1), two wells as Positive control (e.g. E1, F1) and one Blank (e.g. A1, neither samples nor Enzyme Conjugate should be added into the Blank well). If the results will be determined by using dual wavelength plate reader, the requirement for use of Blank well could be omitted. Use only number of strips required for the test.
- 2. Adding Diluent: Add 20 µL of Specimen Diluent into each well except the Blank.
- Adding Sample: Add 100 μL of Positive control, Negative control, and Specimen into their respective wells except the Blank. Note: Use a separate disposal pipette tip for each specimen, Negative Control, Positive Control to avoid cross-contamination. Mix by tapping the plate gently.
- 4. Incubating: Cover the plate with the plate cover and incubate for 60 minutes at 37°C.
- 5. Adding Enzyme Conjugate: At the end of the incubation, remove and discard the plate cover. Add **50 µL** Enzyme Conjugate into each well except the Blank, and mix by tapping the plate gently.
- 6. Incubating: Cover the plate with the plate cover and incubate for **30 minutes at 37°C.**
- 7. **Washing:** At the end of the incubation, remove and discard the plate cover. Wash each well **5 times** with diluted Wash buffer. Each time allow the microwells to soak for **30-60 seconds**. After the final washing cycle, turn down the plate onto blotting paper or clean towel and tap it to remove any remainders.
- Coloring: Add 50 μL of Substrate Solution A and 50 μL of Substrate Solution B into each well including the Blank. Incubate the plate at 37°C for 30 minutes avoiding light. The enzymatic reaction between the Substrate solutions and the Enzyme Conjugate produces blue color in Positive control and HBsAg positive sample wells.
- Stopping Reaction: Using a multichannel pipette or manually, add 50 μL Stop Solution into each well and mix gently. Intensive yellow color develops in Positive control and anti-HBsAg positive sample wells.
- 10. **Measuring the Absorbance:** Calibrate the plate reader with the Blank well and read the absorbance at **450 nm**. If a dual filter instrument is used, set the reference wavelength at **600 650 nm**. Calculate the Cut-off value and evaluate the results. **Note:** read the absorbance within **10 minutes** after stopping the reaction.

#### Instructions for Washing:

- A good washing procedure is essential in order to obtain correct and precise analytical data.
- It is therefore, recommended to use a good quality ELISA microplate washer, maintained at the best level of washing performances. In general, no less than 5 automatic washing cycles of 350-400 µl/well are sufficient to avoid false positive reactions and high background.
- To avoid cross-contaminations of the plate with specimen or Enzyme Conjugate, after incubation do not discard the content of the wells but allow the plate washer to aspirate it automatically.
- Assure that the microplate washer liquid dispensing channels are not blocked or contaminated and sufficient volume of Wash buffer is dispensed each time into the wells.
- In case of manual washing, we suggest to carry out 5 washing cycles, dispensing 350-400µl/well and aspirating the liquid for 5 times. If poor results (high background) are observed, increase the washing cycles or soaking time per well.



- In any case, the liquid aspirated out the strips should be treated with a sodium hypochlorite solution (final concentration of 2.5%) for 24 hours, before liquids are disposed in an appropriate way.
- The concentrated Wash buffer should be diluted **1:20** before use. If less than a whole plate is used, prepare the proportional volume of solution.

### INTERPRETATION OF RESULTS

**Negative Results (A / C.O. < 1):** Specimens giving absorbance less than the Cut-off value are negative for this assay, which indicates that no Hepatitis B virus surface antigen has been detected with Dialab HBsAg Sensitive ELISA, therefore the patient is probably not infected with HBV and the blood unit does not contain hepatitis B virus surface antigen and could be transfused in case that other infectious diseases markers are also absent.

**Positive Results (A / C.O.** ≥ 1): Specimens giving an absorbance equal to or greater than the Cut-off value are considered initially reactive, which indicates that Hepatitis B virus surface antigen has probably been detected using Dialab HBsAg Sensitive ELISA. All initially reactive specimens should be retested in duplicates using Dialab HBsAg Sensitive ELISA before the final assay results interpretation. Repeatedly reactive specimens can be considered positive for Hepatitis B virus surface antigen with Dialab HBsAg Sensitive ELISA.

**Borderline (A / C.O. = 0.9 - 1.1):** Specimens with absorbance to Cut-off ratio between 0.9 and 1.1 are considered borderline and retesting of these specimens in duplicates is required to confirm the initial results.

Follow-up, confirmation and supplementary testing of any positive specimen with other analytical system (e.g. PCR) is required. Clinical diagnosis should not be established based on a single test result. It should integrate clinical and other laboratory data and findings.

#### INITIAL RESULTS INTERPRETATION AND FOLLOW-UP ALL INITIALY REACTIVE OR BORDERLINE SAMPLES



IND = non interpretable

- If, after retesting of the initially reactive samples, both wells are negative (A/C.O.<0.9), these samples should be considered as non-repeatable positive (or false positive) and recorded as negative. As with many very sensitive ELISA assays, false positive results can occur due to the several reasons, most of which are connected with, but not limited to, inadequate washing step.
- If after retesting in duplicates, one or both wells are positive results, the final result from this ELISA test should be
  recorded as repeatedly reactive. Repeatedly reactive specimens could be considered positive for Hepatitis B virus
  surface antigen and therefore the patient is probably infected with HBV and the blood unit must be discarded.
- After retesting in duplicates, samples with values close to the Cut-off value should be interpreted with caution and considered as "borderline" zone samples or uninterpretable for the time of testing.

#### **QUALITY CONTROL AND CALIBRATION**

Each microplate should be considered separately when calculating and interpreting the results of the assay, regardless of the number of plates concurrently processed. The results are calculated by relating each specimen absorbance (A) value to the Cut-off value (C.O.) of the plate. If the Cut-off reading is based on single filter plate reader, the results should be calculated by subtracting the Blank well A value from the print report values of specimens and controls. In case the reading is based on dual filter plate reader, do not subtract the Blank well A value from the print report values of specimens and controls.

#### Calculation of the Cut-off value (C.O.) = Nc + 0.06

(**Nc** = the mean absorbance value for three negative controls).

**Quality control** (assay validation): The test results are valid if the Quality Control criteria are fulfilled. It is recommended that each laboratory must establish appropriate quality control system with quality control material similar to or identical with the patient sample being analyzed.



- The A value of the Blank well, which contains only Substrate Solutions and Stop solution, is <0.080 at 450 nm.
- The A values of the Positive control must be  $\geq 0.800$  at 450/600-650 nm or at 450 nm after blanking.
- The A values of the Negative control must be  $\leq 0.100$  at 450/600-650 nm or at 450 nm after blanking.

If one of the Negative Control A values does not meet the Quality Control criteria, it should be discarded and the mean value calculated again using the remaining two values. If more than one Negative Control A values do not meet the Quality Control Range specifications, the test is invalid and must be repeated.

Example:			
1. Quality Control			
Blank well A value: A1 = 0.025 at 450 nm (Not	te: blanking i	s required	only when reading with single filter at 450 nm)
Well No.:	B1	C1	D1
Negative control A values after blanking:	0.020	0.012	0.016
Well No.:	E1	F1	
Positive control A values after blanking:	2.421	2.369	
All control values are within the stated quality	control range	е	
<b>2.</b> Calculation of Nc: = $(0.020+0.012+0.016)$	/3 = 0.016		
3. Calculation of the Cut-off: (C.O.) = 0.016	+ 0.06 = 0.0	76	

#### PERFORMANCE CHARACTERISTICS

Blood bank C

Total

Evaluation studies carried out in external quality control institutes as well as 3 blood banks, demonstrated the following performance characteristics of HBsAg Sensitive ELISA.

**Specificity:** When evaluated on European blood donors (n=5038), the overall diagnostic specificity of the kit was 99.78%.

During multi-center evalua	tion Dialab HBSAg Sens	Itive ELISA demonstr	ated specificity of	99.92%.	
Laboratory	Number -	Dialab HBsAg Sensitive ELISA			
		-	+	Specificity	
Blood bank A	1958	1955	3	99.85%	
Blood bank B	2518	2516	2	99 92%	

6344

10820

Sensitivity: Dialab HBsAg Sensitive ELISA was evaluated for sensitivity on 22 HBV commercially available HBV seroconversion panels, and on total 403 HBsAg positive including 146 HBsAg HBV genotyped and HBsAg subtyped plasma samples. With respect to seroconversion sensitivity, the results for Dialab HBsAg Sensitive ELISA on the 22 HBV seroconversion panels showed a sensitivity level at least equivalent with the range of current CE marked HBsAg screening assays. 10 additional seroconversion panels were tested in-house. The seroconversion sensitivity was comparable to other CE-marked HBsAg screening tests. With respect to diagnostic sensitivity Dialab HBsAg Sensitive ELISA detected all positive samples as positive, including the HBV genotypes A-F for HBsAg subtypes examined.

6340

10811

4

9

99.94%

99.92%

In conclusion, the overall score of Dialab HBsAg Sensitive ELISA for the seroconversion sensitivity was comparable with other CE marked HBsAg test kits for which PEI holds data and all 403 HBsAg positive samples were reactive giving an overall sensitivity of 100%.

#### Analytical sensitivity: 0.067 IU/mL (NIBSC 00/588)

Analytical specificity: No interference was observed with samples from patients with high-level of rheumatoid factor, and pregnant woman. Same day and frozen specimens have been tested to check for interferences due to collection and storage. Total of 100 samples reactive for anti-HBc, anti-HCV and anti-HIV-1 were screened for HBsAg with Dialab HBsAg Sensitive ELISA. 98 out of 100 samples were negative for HBsAg. 200 blood samples from patients were also tested with Dialab HBsAg Sensitive ELISA. 191 out of 200 samples had negative screening results for HBsAg. 8 out of 9 samples with initial reactive screening results had repeat reactive test results with Dialab HBsAg Sensitive ELISA, but Hepatitis B virus was not confirmed in all cases.

Detection of mutations: Panel of 108 samples collected and sequenced by PCR were tested to demonstrate the performance of Dialab HBsAg Sensitive ELISA in detection of HBsAg mutations. The results are given in the table below.



DIALAB Produktion und Vertrieb von chemisch-technischen Produkten und Laborinstrumenten Gesellschaft m.b.H. IZ NOE-Sued, Hondastrasse, Objekt M55, 2351 Wr. Neudorf, Austria Phone: +43 (0) 2236 660910-0, Fax: +43 (0) 2236 660910-30, e-mail: office@dialab.at

Bac	ckground	Number	Dialab HBsAg Sensitive ELISA
adr (+)	wild type	35	33
	4 mutations	5	4
adw (+)	wild type	37	34
	16 mutations	25	24
ayw (+)	wild type	2	2
	2 mutations	2	2
ayr (+)	2 mutations	2	2
	Total	108	101

#### TRACEABILITY

22 seroconversion panels were used as reference material for the Dialab HBsAg Sensitive ELISA.

#### **EXPECTED VALUES**

Dialab HBsAg Sensitive ELISA is a qualitative assay and cannot be used to measure the antigen concentration, therefore the concept of expected values is not applicable. Example values for absorbance can be found in the chapter QUALITY CONTROL AND CALIBRATION:

#### LIMITATIONS

- Positive results must be confirmed with another available method and interpreted in conjunction with the patient clinical information.
- Antigens may be undetectable during the early stage of the disease. Therefore, negative results obtained with Dialab HBsAg Sensitive ELISA are only indication that the sample does not contain detectable level of Hepatitis B virus surface antigen and any negative result should not be considered as conclusive evidence that the individual is not infected with HBV or the blood unit is not infected with HBV.
- If, after retesting of the initially reactive samples, the assay results are negative, these samples should be considered as non-repeatable (false positive) and interpreted as negative. As with many very sensitive ELISA assays, false positive results can occur due to the several reasons, most of which are related but not limited to inadequate washing step.
- The most common assay mistakes are: using kits beyond the expiry date, bad washing procedures, contaminated reagents, incorrect assay procedure steps, insufficient aspiration during washing, failure to add specimens or reagents, improper operation with the laboratory equipment, timing errors, the use of highly haemolyzed specimens or specimens containing fibrin, incompletely clotted serum specimens.
- The prevalence of the marker will affect the assay's predictive values.
- This assay cannot be utilized to test pooled (mixed) plasma. Dialab HBsAg Sensitive ELISA has been evaluated only with individual serum or plasma specimens.
- Dialab HBsAg Sensitive ELISA is a qualitative assay and the results cannot be used to measure antigen concentration.

#### WASTE MANAGEMENT

Reagents must be disposed of in accordance with local regulations.

#### LITERATURE

- 1. Stevens, C. E., P. E. Taylor, and M. J. Tong. 1988. Viral hepatitis and liver disease. Alan R. Riss, New York, N.Y. 142. Stevens, C. E., P. E. Taylor, M. J. Tong, P. T. Toy, G. N. Vyas, P. V. Nair,
- J. Y. Weissman, and S. Krugman. 1987. Yeast-recombinant hepatitis B vaccine. Efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission. JAMA 257:2612–2616. 143. Stevens, C. E., P. T. Toy, P. E. Taylor, T. Lee, and H. Y. Yip. 1992. Prospects for control of hepatitis B virus infection: implications of childhood vaccination and long term protection. Pediatrics 90(Suppl.):170–173.
- 3. Hurie, M. B., E. E. Mast, and J. P. Davis. 1992. Horizontal transmission of hepatitis B virus infection to U.S. born children of Hmong refugees. Pediatrics 89:269–273.
- Szmuness, W., C. E. Stevens, E. J. Harley, E. A. Zang, W. R. Olesko, D. C. Williams, R. Sadovsky, J. M. Morrison, and A. Kellner. 1980. Hepatitis B vaccine: demonstration of efficacy in a controlled trial in a high risk population in the U.S. N. Engl. J. Med. 303:833–841.
- Bhatnagar, P. K., E. Papas, H. E. Blum, D. R. Milich, D. Nitecki, M. J. Karels, and G. N. Vyas. 1982. Immune response to synthetic peptide analogues of hepatitis B surface antigen specific for the a determinant. Proc. Natl. Acad. Sci. USA 79:4400–4404

#### USED SYMBOLS

Symbol

Description

Cont.

Content





